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 INTRODUCTION 1 
1 INTRODUCTION  
Dietary habits have long been suspected to take part in the development of 
widespread multifactorial illnesses like cardiovascular disease and cancer. Modification 
of lifestyle to include daily intake of plant-based food containing anticancer and 
antiinflammatory phytochemicals represents a promising approach to prevent their 
development. Vegetable diet contains plenty of  “bioactive compounds”, extra-
nutritional constituents that typically occur in small quantities and exhibit capacity to 
influence molecular events. Since it has been documented that deficiency of certain 
nutrients may induce inadequate gene expression and failure in genomic integrity 
(Cheng 2009), nutritional science has investigated a plethora of different food 
components  playing a role in regulating the genomic machinery.  
Cancer growth and metastasis are due to coordinated change in expression of a set of 
genes, for which genetic alterations can not solely be blamed. It is becoming apparent 
that a lot of observed alterations in gene expression are generated by epigenetic 
modifications (Szyf 2005). Epigentic modifications are potenially reversible, opposed to 
DNA mutations and therefore are covetable targets for potential chemoprevention 
strategies and therapy. Since epigenetic alterations can be early incidences in 
carcinogenesis, reversal of inaccurate epigenetic patterns is aimed to affront pre-
neoplastic cells before final carcinogenic changes occur (Myzak and Dashwood 2006).  
Epigenetic influences of several bioactive food compounds might be mechanisms of 
disease prevention by not only being able to have gene-nutrient interaction but also by 
modifying methylation marks in specific gene regions or global DNA methylation, 
linking nutrition with modulation of gene expression (Ross and Poirier 2002). The 
impact of bioactive food components on genespecific DNA methylation is less clearly 
understood than their effect on global DNA methylation (Davis and Uthus 2004). 
Nevertheless understanding DNA methylation patterns of disease asscoiated genes 
through interaction with nutrients is elementary to explain pathophysiological 
processes responsible for the appearence or absence of certain ailments and to 
eventually evolve into prevention  and therapeutic strategies for risk populations.  
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2 SCIENTIFIC BACKGROUND 
2.1 The Mammalian Epigenome  
 
Genetics alone cannot explain human variation and disease. Even though possessing 
the same DNA sequence, monozygotic twins and cloned animals display different 
phenotypes, occurence and penetrance of illnesses. The epigenetics field of research 
tries to find partial explanation for these phenomena. The term epigenetics describes 
mechanisms inducing changes in gene expression or phenotype not caused by 
alterations in the underlying DNA sequence, which are established during 
development or somatic cell prolieferation and transmitted through mitosis. 
Compared to the genome, which is almost identical in different cell types and 
consistent  throughout life, the epigenome is varying between different cell types as 
well as over the course of a  lifetime (Szyf 2005). 
The Human Epigenome Project aims to uncover the missing link between genetics, 
disease and enviroment by investigating the regulation of gene expression through 
epigenetic remodelling of chromaine strucure by identifiying and interpreting genome 
–wide DNA methylation patterns of all human genes in all major tissues. Further 
mechanisms to configurate chromatin architecture and change gene expression are 
histone modification and micro RNAs (Holliday 2006). 
 
2.1.1 DNA methylation  
 
The epigenetic modification most thoroughly 
investivated is DNA methylation. In eukaryotic 
organisms the adherence of a methyl group to the 
DNA occurs specifically in the carbon -5 position of 
cytosines followed by guanosine, in so-called CpG 
dinucleotides and might have evolved both as a 
protective mechanism against parasitic DNA 
elements and as a regulatory machinery in more complex genomes. DNA methylation 
 
Figure 1: DNA Methylation        
                (www.hgu.mrc.ac.uk) 
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has been implicated in appropriate embryonic development, X-chromosome 
inactivation and control of monoallelic expression of genes via genomic imprinting. 
Cytosines in CpG arrangements are receptive to methylation, facilitating discrimination 
between newly synthesized and parental DNA strands and eventually supporting DNA 
proofreading after duplication (Fatemi, Hermann et al. 2002; Esteller 2008). CpG 
dinucleotides make up even less than they statistically should in the entire genome.  
This rarity of CpGs might be due to the mutability of 5-methylcytosine, being prone to 
turn into thymines after spontaneous deamination. The same mechanism seems to be 
responsible for the inactivation of retroviruses by changing the virus sequences 
(Morgan, Santos et al. 2005).  
 In mammals the majority of CpGs is methylated and throughout a large part of the 
genome CpGs are sparsely spread but concentrated in short stretches or clusters, so 
called CpG islands (CGI). CGIs are of between 0.5 kb and 2 kb length and commonly 
span the promoter region of ubiquitiously expressed “housekeeping” genes and the 3´ 
or 5´ regions of a number of tissue specific genes. Alltogether CpGs occur in about half 
of all human genes. Approximately 80% of the CpG dinucleotides outside of CGIs are 
heavily methlyated, in contrast those in promoter regions are usually unmethylated. 
The bulk of CpGs though are located at low density within transposable elements and 
repeat sequences (Davis and Uthus 2004; Agrawal, Murphy et al. 2007; Hinshelwood, 
Melki et al. 2009). 
CpG methylation is known to mostly repress gene transciption, as methylated DNA can 
hinder binding of transcriptional factors or attrac protein complexes, so called methyl-
CpG-binding domain proteins (MBDs), promoting histone modification and therefore 
leading to chromatin compaction and gene silencing, whereas unmethylated CGIs are 
associated with transcriptionally active loosened chromatin. DNA methyltransferases 
catalyze transferation of methylgroups to carbone 5 of the cytosine ring, by using S-
adenosylmethionine (SAM) as a methyl donor (Grafi, Zemach et al. 2007). The DNA 
methylation pattern has to be duplicated together with the genetic information at any 
cell mitosis. Recopying DNA methylation is mediated by DNA methyltransferase-1 
(DNMT1), which is incorporated in the DNA replication complex and preferentially 
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methylates CpGs on hemimethylated DNA strands (Bestor 2000). Since aberrant 
methylation patterns are transmitted through mitosis, abnormal methylation might 
undergoe clonal expansion, changing gene expression and lead to phenotypic changes 
comparable to a mutation (Johnson and Belshaw 2008). DNA methyltransferases 3a 
and 3b are said to be responsible for de novo methylation, which is especially 
distinctive during embryogenesis whilst first cleavage divisions. Here DNA methylation 
is reconstituted after an almost absolute demethylation. But de novo methylation also 
appears later  in development and actually in mature adult cells in order to silence 
aquired proviral DNA or to change the cell´s developmental program. Data suggests 
that DNMT1 also participates in de novo methylation. De novo-activity is stimulated by 
binding of methylated DNA to an allosteric site in the enzyme´s N- terminal domain, 
appearing to cooperate with DNMT3a, which initiates methylation processes by 
delivering methyl groups to one region of the DNA, leading to recruitment of DNMT1, 
which proceeds methylating the whole DNA domain. All three methyltransferases are 
essential for development and viability, as knockout mutations in any of these genes 
lead to fetal or postnatal death in mice (Fatemi, Hermann et al. 2002). 
 
2.1.2 Histone modification  
 
Chromatine in the eukaryotic nucleus is a complex of DNA and histones, which are 
octamers of two of each H2A, H2B, H3 and H4 and 147 base pairs of DNA. An 
additional histone, H1 serves as an anchor to fasten the DNA to the nucleosome. 
Acetylation, biotinylation, methylation, phosphorylation ubiquitination, SUMOylation, 
glycosylation, carbonylation and ADP ribosylation are processes to posttranslationally 
modify the core histone´s protruding N-terminal tail and thus change chromatin 
stucture. Combinations of these modifications determine interactions between histone 
and DNA as well as between chromatine and regulatory proteins. The “histone code” 
hypothesis declares a given modification of a certain histone residue to be a 
prerequisite for a succesive modification on the same or adjacent histone, leading to 
altered DNA configuration and extending the information potential of the genetic code. 
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Alterations in the configuration of chromatin structure are connected to changes in 
gene expression with euchromatine, densly packed and transcriptionally inactive and 
loose heterochromatine, representing transcriptionally active regions, as regulatory 
proteins and transcription factors are able to bind to the DNA. Proteins containing 
bromo- and chromodomains have been reported to bind to acetylated- and 
methylated lysines respectively. Heterochromatine protein -1 (HP1) for instance is 
needed for the formation of heterochromatin. It possesses chromodomains 
cooperating with a trimethylated H3K9 (histone 3-lysine 9) and attracting SUV39H1, a 
histone H3K9 methylase that subsequently methylates the neighbours nucleosome H3  
ending at lysine 9 to cause HP1 binding and further distribution of heterochromatic 
regions (Yoo and Jones 2006; Delage and 
Dashwood 2008).  
Acetylation is one of the most popular 
histone modifications. Transfer of acetyl-
coenzyme A as a donor group to  lysine 
residues of histones H4 and H3 is 
catalyzed by histone acetyltransferases 
(HATs).  Histone acetylation is associated 
with transcriptional activation, since 
alteration in histone- DNA binding, due 
to lysine loosing a positive charge, leads 
to a more incoherent DNA configuration 
and facilitate binding of transcription 
factors  (Turner 2002). 
Balance between enzymatic activity of HATs and histone deacetylases (HDACs) 
determines the extend of histone acetylation. Four families of HDACs are well known 
and classified due to their function and homology to yeast Saccharomyetes cerevisiae: 
Class I (HDAC 1-3,8) is mainly found in the nucleus and class II ( HCAC 4-7,9) can shuttle 
signal dependently between nucleus and cytoplasm. Class I and II are selectively 
inhibitable by trichostatin, an organic compound that serves as an antifungal antibiotic. 
 
 
 
 
Figure 2: Histone Acetylation  
                 (Huang 2009) 
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Class IV is an atypical category based only on DNA sequence homology to the other 
classes. Solely class III ( sirtuins 1-7), named after yeast protein Sir2 (silent information 
regulator 2) due to their analogy, is structured differently to class I,II and IV HDACs and 
also alters in the enzymatic mechanism, as sirtuins use NAD+ as a cofactor (Villar-
Garea and Esteller 2004). SIRT1 was found out to participate in basal cellular processes, 
such as antiapoptosis, cellular senescence, aging and longevity (Kikuno, Shiina et al. 
2008).  
Another well investigated mechanism is histone methylation, which is linked to both 
transcriptional activation and repression, depending on the residue it is attached to. 
Lysine and arginine residues are targets for histone methyltransferases (HMTs) and 
histone demethylases (HDMs), wich mono-, di-  and trimethylate lysine or 
monomethylate arginine histone tails (Turner 2002).  
H3K4 methylation for instance is known to be an activating and H3K9 as well as 
trimethylation of H4K20 to be an inactivating marker. Mono- and dimethylated H3K9 
are present in transcriptionally inacitve, euchromatic regions compared to 
trimethylated H3K9, commonly found in pericentromeric heterochromatin.  
Nevertheless, methylated H3K9 has even  been found in region of active transcription. 
Accordingly, further studies are necessary to discover the full extend of these precise 
mechanisms (Laird 2005). 
 
2.1.3 Micro RNAs 
 
First micro RNAs (miRNAs), lin-4 and let-7 were identified 1993 in Caenorhabditis 
elegans as fundamental development regulators. By now a multitude of miRNAs were 
discovered to play crucial roles in several biological pathways, affecting gene 
expression on the posttransciptional level. They are highly conserved, of 18 - 24 
nucleotide length and regulate cognate mRNAs by blocking through basepairbinding or 
by degradation. Target mRNAs are attacked usually at the partially complementary 
sites in the 3´untranslated region (He and Hannon 2004). Genes for miRNAs are 
arranged in the genome and biosynthesis is initiated with transciption by an RNA 
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polymerase II into capped and polyadenylated primary (pri-) miRNAs which form loops. 
RNAse III, so called Drosha, and the double stranded RNA binding protein DGCR8 
(DiGeorge syndrome critical region) form a microprocessor complex, generating a ~ 
70nt  hairpin precursor (pre-) miRNA. Nuclear export factor exportin 5 transportes pre- 
miRNAs from nucleus to the cytoplasm, where they are digested by another double 
strand specific ribonuclease, Dicer, into an imperfect  2nt 3´overhanging, 18-24 
nucleotide miRNA duplex. The duplex is incorporated into the RISC complex (RNA – 
induced silencing complex) preferably at its weakest base pairing at the  5´ terminus. 
Argonaute proteins, also being 
included in the complex, remove 
one strand of the miRNA duplex 
while the other one remains 
solidly bound to the RISC 
complex (Gregory, Chendrimada 
et al. 2005). RISC complex is 
conducted by mature miRNA  to 
the target RNA, provoking its de-
gradation through imperfect 
complementary miRNA-mRNA 
base pairing, or its translational 
silencing (He and Hannon 2004). 
MiRNA induced mRNA de-
gradation is presumed to take place in so called p-bodies and the exact mechanism of 
miRNA induced disabled translation remains unexplained, since initiation as well as 
translation seem to be concerned (Liu, Valencia-Sanchez et al. 2005).  
On the contrary, evidence also indicate miRNAs to enhance translation of mRNAs. 
MicroRNAs oscillate between repression and activation depending on the stage of cell 
cycle. They inhibit translation in proliferating cells and induce activation in G1/G0 arrest 
(Vasudevan, Tong et al. 2007). 
 
Figure 3: Biogenesis of microRNAs  
              (www.nature.com) 
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Next to micro RNAs three additional types of small RNAs have been found in animals: 
small interfering RNAs (siRNAs), repeat associated small interfering RNAs and Piwi- 
interacting RNAs (piRNAs). SiRNAs, genereated out of double stranded RNA and  
originated from viruses or overlapping transrcipts, match perfectly to their target 
mRNA and trigger degradation. Rasi RNAs were explored in Drosophila and emerge 
from antisense strands of genomic repeats or retrotransposons. PiRNAs are a germline 
specific class of small RNAs, existing in vertebrates and operating by attaching to Piwi 
proteins, a subfamily of Argonaute proteins.  
MiRNAs are expressed tissue specifically during development, hinting at miRNAs to be 
eventually involved in differentiating and maintaining tissue identity (Kloosterman and 
Plasterk 2006). More than 500 human miRNA genes have already been identified 
(Sevignani, Calin et al. 2006) and the human  genome is assumed to encode roughly a 
1000, whereas the function of most mammalian miRNAs is not known. Each miRNA is 
said to have hundreds of evolutionary conserved targets and even more unconserved 
ones, which gives reason to speculate about 30% of the genome to be regulated by 
miRNAs (Davis and Ross 2008). For cells producing transcripts instead of proteins is 
energetically less costly and might be the reason why regulation at the RNA level is 
more efficient than on protein level (Sevignani, Calin et al. 2006). 
 
2.2 Cancer Epigenetics  
 
Cancer cells can be discribed to be immature, grow abnormally and generally lead to 
uncontrolled proliferation, sometimes loose attachment and metastazise. 
Scientists investigating the principles of why and how organisms develop cancer, until 
recently focused studying a diversity of genomic and genetic alterations like point 
mutation, deletion, amplification and translocation. These findings built the 
groundwork for identifying oncogens and tumor suppressor genes. Nowadays, 
ascertainment of the  importance epigenetic influences have on the generation of 
neoplasia has led to extensive efforts to study epigenetic modifications in the 
neoplastic cells.  A majority of research has concentrated on the role DNA methylation 
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has on genexpression under physiological and pathological conditions. Aberrant DNA 
methylation is not only involved in tumorigenic events but also in several other 
ailments like cardiovascular diseases, the metabolic syndrome and neurological 
diseases. Genetic syndromes also contain epigenetic components. The Rett syndrome 
for example is caused by mutation in the MeCP2 gene (methyl-CpG-binding protein) 
and patients with ICF (immunodeficiency, centromer instability and facial anomalie) 
suffer from a mutation in DNMT3b. Cells` DNA of lupus patients were detected to be 
hypomethylated and methylation of the fragile X mental retardation-1 (FMR) gene is 
involved in the same titeled disorder (Robertson and Wolffe 2000; Esteller 2008). 
 
2.2.1 Epigenetic patterns in cancer  
 
Neoplastic developments involve aberrant regulation of multiple genes. In cancer cells 
fundamental epigenetic changes arise, causing aberrant gene expression patterns and 
leading to uncontrolled cell cycle progession and cell growth.  
 
DNA methylation in cancer cells 
In healthy cells, majority of the CpGs in genes or promoter regions are unmethylated, 
allowing genes to be transcribed when stimulated by appropriate transcription factors. 
In certain cases gene promoters can be methylated as a part of the common 
developmental process. Genomic or parental imprinting early in the germline requires 
a compact chromatine state and DNA hypermethylation in one allel of for instance 
growth-related genes, to ensure monoallelic expression. Similar gene switch off 
mechanism is observed in X-chromosome inactivation in women. Tissue specific 
expression pattern can also to some extend be attributed to DNA methylation (Esteller 
2008). 
Two major events happen in the DNA methylation landscape of neoplastic cells:  
On the one hand the entire genome becomes hypomethylated, on the other hand 
intense hypermetylation occurs mainly in promoters of cancer related genes (Davis 
and Uthus 2004). Genome hypomethylation is an early event in neoplastic 
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development and assembles during all cancerogenic steps. Its extent correlates with 
the degree of tumor aggressiveness (Esteller 2008). Cancer progression might be due 
to loss of imprinting induced by global hypomethylation, reactivating silenced 
transposable elements and endogenous retroviruses. Transposable elements might 
also endorse genomic mutations and unregular chromosomal recombinations, 
furthermore hypomethylation could cause chromosomal instability (Davis and Uthus 
2004). Hypomethylation of centromeric sequences usually occurs in neoplastic cells, 
eventually generating aneuploidy (Esteller 2008). Abnormal CpG hypermethylation 
commomly occurs in the promoter region of tumor suppressor genes, leading to 
inhibited expression of genes affecting virtually all cellular functions, such as cell cycle 
(p16INK4a , p15INK4, Rb), hormonal response (ESR1), apoptosis (DAPK, APAF-1), 
carcinogen metabolism (GSTP1), DNA repair (hMLH1, BRCA1) and cell adherence 
(CDH1 and 3, E-cadherin) (Davis and Uthus 2004). It has also been reported, that 
exonic CpG islands of p16INK4a , p15INK4 were more susceptible to de novo methylation 
than promoter CpG islands. Methylation might be seeded in exonic regions, 
wherefrom it could spread to other islands, including promoter regions. Subsequently, 
cell selection due to growth or multiplication advantage, emerged from spread of 
methylation into and inactivation of certain promoter regions, could generate the 
development of a specific type of cancer (Nguyen, Liang et al. 2001). Particular 
methylation inactivated genes are reported to be strongly tissue specific. Thus, a tissue 
specific profile of CpG hypermethylation exists in human cancer, potentially serving as 
biomarker in the detection of malignant disease with unknown origin (Davis and Uthus 
2004). Colorectal cancers and adenomas for instance have been reported to show 
what was termed to be a “CpG island methylator phenotype”, a status characterized 
by coincidantal hypermethylation of a number of defined genes (Hinshelwood, Melki 
et al. 2009). 
Reasons for global hypomethylation and loci specific DNA hypermethylation remain 
unclear. Several mechanisms are discussed: Overexpression of DNMT3b4, an inactive 
splice variant of DNMT3b, correlates with the degree of DNA hypomethylation on 
pericentromeric satellite regions of preneoplastic and neoplastic tissues. Moreover, 
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DNMT1 deficiency in APC mutant gene carrying Min mice caused a prevention of 
tumor development (Laird, Jackson-Grusby et al. 1995).    
DNA methyltransferases have been shown to bind with higher affinity to broken DNA 
strands, abasic sites and uracil than they bind to their cognate hemimethylated DNA 
strand sites, in analogy to their ancestral function as DNA repair enzymes. It has been 
hypothezised that DNA lesions, which apppear frequently in human tumorigenic DNA, 
may be required for the disruption of normal DNA methylation patterns (Davis and 
Uthus 2004). 
 
Histone modification in cancer cells 
Changes in DNA methylation are closely associated with those in histone modification. 
Similarly to DNA methylation, disarranged global genome histone patterns, with both 
loss and gain of histone lysine acetylation and methylation have been reported in 
transformed cells. Primary event of gene silencing seems to be loss of lysine 
acetlyation whereas enhanced histone methylation occurs afterwards. Thus HDACs are 
appointed to be one of the major targets for therapy. Diminished acetylation does not 
exclusivley lead to gene silencing as it can also result in degraded DNA repair, 
escalating the risk of evolving neoplastic cells. HDA1, a class II HDAC homologue in 
Caenorhabditis elegans, participates in controlling cancer related extracellular as well 
as tissue specific genes and  abnormal telomer elongation might be caused by loss of 
H3-K9 methylation in mice (Yoo and Jones 2006). The majority of aberrant histone 
modifications due to inappropriate targeting of one or more histone modifying 
enzymes were discovered at individual gene promoters. E2F transcription factor, for 
example, recruits retinoblastoma protein (Rb), a tumor suppressor, to its target genes 
and Rb in turn attracts HDAC1, leading to transcriptional silencing of genes such as 
Cyclin E, participating in cancerogenic pathyways (Brehm, Miska et al. 1998). Studies 
using chromatin immunoprecipitation (ChIP), a method determining sites of protein – 
DNA interaction, found p16INK4A tumor suppressor silencing to be associated with 
hypermethylation of H3K9 and hypomethylation of H3K4 (Meng, Zhu et al. 2007).  
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           Figure 4: DNA methylation and histone modification in normal and cancer cells  
                          (Kristensen, Nielsen et al. 2009) 
 
 
 
MicroRNA expression in cancer cells 
Abberant expression profile of the miRNome has been documented to correlate with 
several human diseases including neurodegenerative illnesses and diabetes. As 
miRNAs regulate cellular processes like apoptosis, proliferation and differentiation 
they are also involved in the pathophysiology of all types of human cancer.  (Sevignani, 
Calin et al. 2006). The reason for miRNAs abnormal regulation in cancer cells might be 
their prevalent location at fragile sites, sites of loss of heterozygosity, amplification and 
common breakpoint regions, which are susceptible to genetic alterations in cancer 
cells, leading to altered miRNA expression in cancer (Davis and Ross 2008). 
Furthermore loss of expression of several miRNAs could be due to CpG 
hypermethlation on their regulatory region, as demethylating agents are able to 
induce reexpression of for example miR-127 and downregulation of its putative target 
proto – oncogen BCL-6. In contrary, epigenetically silenced miR-124a causes activation 
of Cyclin -D -kinase 6, an oncogenic factor and subsequent phosphorylation of cell 
cycle regulator Rb and cell cycle progression (Esteller 2008). Some data reveal that 
downregulation of certain subsets of miRNAs occures commonly in cancerous cells, 
leading to the suggestion, that they might function as potential tumor suppressors or 
participate in tumor suppressor signaling pathways (Davis and Ross 2008; Esteller 
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2008). P53, being one of the most frequently mutated genes, transcriptionally 
regulates levels of miR-34 through direct binding to the promoter region. In addition, 
DNA damage can induce activation of miR-34 in wild type animals but not in p53 knock 
outs. Ras oncogen overexpression, present in 15-30% of all cancers, seems to be 
regulated by miRNA. Studies conducted in lung cancer patients showed, that low level 
of let-7 correlated with poorer prognosis after surgery, as let-7 was demonstrated to 
target a number of genes involved cell cycle regulation (Zhang, Gao et al. 2009).  
 
2.2.2 Epigenetic biomarker and diagnostics 
CGI methylation aberration occurs early and is functionally operative in carcinogenesis, 
therefore it offers potential biomarkers to assess an individual's risk of having or 
developing neoplasia (Belshaw, Elliott et al. 2008). Several genes have the potential to 
serve as DNA methylation biomarkers for early cancer diagnostics or for predicting 
prognosis and response to therapy.  
Being a stable molecule, as opposed to RNA, DNA can simply be extracted from tissues 
and easily accessible body fluids like blood, sputum or urine, potentially allowing early 
recognition and diagnosis of tumors and screening of high-risk populations. Circulating 
tumor derived material has been detected to reflect methylation pattern of different 
types of primary tumors. P16INK4a promoter methylation, in the sputum of smokers for 
instance, has been assessed to be a biomarker for early detection of lung cancer.  
Futhermore, isolation of DNA, carrying the methylation information out of formalin 
fixed, paraffin embedded (FFPE) tissue, displaying the bulk of clinical archived tissue, 
and subsequent PCR technique can be conducted without any difficulty. Moreover, 
sample handling for subsequent methylation analysis is not as elaborat as for cDNA or 
protein expression assays. Methylation signals are easier detectable in comparison to 
loss of heterozygosity or changes in gene expression, which are delicate to discover 
when plenty of normal DNA is “disturbing”. Since measurement of DNA methylation 
via mulitplex PCRs and DNA methylation microarrays enables detection of multiple 
genes all at once, identification of cancer tissue specifc DNA methylation profiles was 
highly simplified (Paluszczak and Baer-Dubowska 2006; Kristensen, Nielsen et al. 2009). 
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Measuring promoter methylation of p16INK4b, p15INK4a, RASSF1A and ESR1 has been 
determined to be a epigenetic biomarker in a noninvasive approach to early detection 
of hepatocellular carcinoma and non small lung cancers in high-risk patient population. 
Methylated DNA sequences in serum correspond to cancer-related epigentic events in 
occult tumors, suggesting that DNA sequences shed from tumors into blood might 
represent a potentially valuable biomarker for preclinical detection of neoplastic 
events. In some cases methylated allels could even be detected years before clinical 
diagnosis (Rivenbark and Coleman 2007; Suga, Miyajima et al. 2008). Thus DNA 
methylation measurement has also been shown to have predicitve abilitys. 
Methylation of p15INK4b´s and estrogen receptor´s promoter site for instance forecasts 
poor prognosis in patients with early stage myelodysplastic syndrome and 
hypermethylation of E-cadherine was negativley correlated with disease free survival 
in oral toungue carcinoma as well as with early recurrance in gastric stromal tumors. 
Methylation detection might also have promising potential in the molecular 
monitoring of disease after therapy. DNA hypermethylation has been associated with 
the prediction of response to chemotherapy. Two established hypermethylation 
markers of clinical response to therapy are largely debated: MGMT and missmatch 
repair gene hMLH1. Hypermethylation of MGMT can be seen ambivalently, since in 
early tumor stages diminished expression affects cells´ defense against carcinogenic 
DNA alkylating agents whereas hypermethylation in present cancer conditions 
response to alkylating drugs. Loss of mismatch repair often caused by hMLH1 
promoter hypermethylation is associated with resistance to clinically fundamental 
drugs. Methyltransferase inhibitor 5 aza-2´-deoxy azacytydine dependent demethyla-
tion of hMLH1 reversed resistance to cisplatine, carboplatin and several more 
chemotherapeutics (Paluszczak and Baer-Dubowska 2006; Kristensen, Nielsen et al. 
2009). Levels of several HDACs have also been recommended to eventually serve as 
potential biomarkers and detection of extent of histone acetylation might be a good 
parameter to measure clinical response to HDAC inhibitors (Stimson and La Thangue 
2009). 
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MiRNAs are more stable than mRNAs, giving the possiblity to quantitativley recover 
them from formalin- fixed paraffinembedded tissues (Davis and Ross 2008). Large scale 
miRNA microarrays have been used to determine and compare miRNA expression 
profiles in healthy cells and tissues to those in cancers, determining distinct miRNA 
patterns to be associated with certain tumor types. Researchers even claime to more 
successfully classify poorly differentiated tumours, by the use of miRNA expression 
profile than by messenger RNA profiles, underlining the capability of miRNA profiling in 
cancer diagnosis and therapy planning (Lu, Getz et al. 2005).   
 
2.2.3 Epigenetic therapy  
 
The insight in aberrant epigenetic patterns in malignant cells and potential reversibility 
of epigenetic modifications leads to an extensive quest for new drugs, offering a 
promising opportunity for novel cancer treatment.  
 
DNA methylation inhibitors / DMNT inhibitors 
DNA methylation inhibitors can be classified into nucleoside analogues and non 
nucleoside analogues. Nucleoside analogues have a modified cytosine ring, which is  
affixed to a ribose or deoxyribose residual. They are processed by kinases transforming 
nucleosides into nucleotides to integrate them into DNA or RNA. Methylation of those 
altered cytosines is unfeasible, as modifications at carbone 5 leads to the formation of 
a covalent complex preventing the release of DNMTs.  5 –azacytidine (azacitidine) and 
5- aza-2´ deoxycytidine (deacatabine) have been the first “epi-drugs” to be synthesized 
and are potent DNA methylation inhibitors at micromolar concentration. These agents 
have been thoroughly investigated for treatment of haematological diseases and have 
been approved for treatment of myelodysplasia. Unfortunately, short half lives in 
aqueous solutions, their instability even in neutral pHs and their cytotoxicity 
complicates their delivery. Anyhow, tumor suppressor gene demethylation already 
takes place at low, not cytotoxic concentrations, allowing elongated treatment 
duration to ensure persistent demethylating effects (Yoo and Jones 2006; Kristensen, 
Nielsen et al. 2009). 
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In comparison to azacitidine, further nucleoside analogues like 5-fluoro-
2´deoxycytidine and zebularine are much more stable and less cytotoxic (Cheng, Yoo et 
al. 2004). A handful of non-nucleoside analogues have been described to inhibit DNA 
methylation but not many of them reached clinical trials. These molecules suppress 
DNA methylation by directly binding to DNMTs catatlytic region, without being 
incorporated into the DNA. RG108 was designed to accurately fit into the catalytic 
pocket of human DMNT1 and suppresses its activity, whereas MG98 prevents 
translation of DNMT1 by binding to its mRNA. Anticancerous effects of these 
substances have been observed in several solid cancers in phase I studies. The 
demethylating effects of epigallocatechin-3-gallate, hydralazine and procainamide 
have been compared to deacatabine in a study, drawing the conclusion that 
deacatabines, and accordingly the potential of nucleoside analogues in general, is far 
more effective (Chuang, Yoo et al. 2005). MicroRNA expression seems also to be 
enhanced by DNMT inhibitors subsequently modyfing the epigenome independent 
from DNA methylation (Kristensen, Nielsen et al. 2009). Natural sponge Pseudo-
ceratina pupurea components, so called psammaplins, are a group of bromo tyrosine 
derivates inhibiting both: DNA methyltransferases and histone deacetylases (Yoo and 
Jones 2006).  
 
HDAC inhibitors 
Since different diseases have been associated with abnomal expression of different 
HDAC isoforms, many drugs with HDAC suppressing effects have been described and 
plenty of them are participating in ongoing clinical trials. Most substances function 
through interference with HDAC´s catalytic domain, blocking substrate recognition and 
inducing gene expression. With many existing enzymes implying the highly conserved 
catalytic domain of class I,II and IV HDACs, it is hard to design isoform specific 
inhibitory drugs. Most of the listed substrates target class I and II HDACs , which are 
zinc- dependent. HDAC inhibitors are very diverse in origin and structure. Based on  
chemical properties they can be divided into different categories. Sodium butyrate and 
valproic acid belong to the group of short chain fatty acids. Valproat has been reported 
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to degrade HDAC2 in a proteasome and potentially reduce breast cancer tumor growth 
and metastazation in rodents and a phenylbutyrate derived HDAC inhibitor named 
OSU-HDAC42 demonstrated promising effects on ovarian and hepatocellular cells by 
inducing apoptosis as well as prevention of tumor progression to less differentiated  
prostatatic intraepithelial tumors in mice (Kristensen, Nielsen et al. 2009). 
Hydroxamic acids form another class of HDAC inhibitors comprising trichostatin, 
vorinostat, panobinostat and belinostat. Their mutuality is the zinc-binding group, 
which is analogous to N-acetylated lysines acetyl group, chelating zink ions in their 
cylindrical pocket (Butler and Kozikowski 2008). 
Trichostatin A is a very potent HDAC inhibitor having many antitumorigenic effects. But 
due to its severe side effects it is not applied in clinical trials. Belinostat has shown 
good antitumorigenic effects in ovarian xenograft tumors and suppressed bladder and 
prostatate cancer growth in vivo and in vitro, partially by enhanced expression of       
p21 WAF1. Vorinostat is utilized in combination with other chemotherapeuticals in class I, 
II and III clinical tirals. Nevertheless a noted problem among hydroxyamic acids is, that  
they are unselective to HDAC isoforms. Cyclic peptide romidepsin (FK228), being 
activated due to reduction of its disulfide bond, displays a further class of HDAC 
inhibitors and has been reported to function against human tumor xenografts and 
murine tumors. Benzamide, entinostat (MS – 274) and MGCD- 0103 for instance, exibit 
2´aminoanilide residues, acting as weak zinc-chelating group, and thus leading to 
interference with HDACs catalytic domain. In the end, several microarray studies have 
demonstrated that HDAC inhibitors generally concern only a small section of the 
transcriptome (Kristensen, Nielsen et al. 2009). The amplitude of interactions HDACs 
have with non-histone proteins such as transctiption factors, DNA repair enzymes, 
chaperone proteins, structural and signal transduction proteins makes it difficult to 
exactly predict effects and to generate HDAC inhibiors, which are able to reactiavate 
targeted genes without unwanted outcomes  (Su, Altucci et al. 2008).  
Finally synergistic effects of DNMT and HDAC inhibitors in combined treatment  
strategies have been observed in various studies on different cancer cell cultures and 
rodent studies (Kristensen, Nielsen et al. 2009). As “epi-drugs” impact is transient and 
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with discontinuity of treatment, aberrant epigenetic patterns can return and malignant 
cell population is able to reappear. An advantage of epigenetic drugs is that most of 
them function at low doses, showing hardly any cytotoxic effect and therefore being 
applicable over a certain time (Yoo and Jones 2006).  
  
2.2.4 Environmental and nutritional influences on DNA Methylation and 
cancer susceptibility 
 
The health of organisms and their offspring is modifiable by interactions between  
enviroment, nutrition and the genome. Since epigenetic events are receptive for 
modification they might  explane how environmental factors, such as diet, modify 
cancer risk. 
Statistical evidence demonstrates that our ancestors life circumstances, auch as food 
availability impacts life expectancy of subsequent generations. This longevity effect 
was attributed to epigenetic inheritance (Kaati, Bygren et al. 2007). 
Changes in dietary habits in Japan for instance, altered the incidence of several 
cancer´s appereance, providing strong evidence for the importance of diet as a 
enviromental factor in the aetiology of diseases (Hinshelwood, Melki et al. 2009).   
A multitude of biologically active food compounds have been described to impact DNA 
methylation directly and by enzyme activity interference, some of which are discussed 
in this study and indirectly by metabolic processes associatd with energy metabolism 
(Johnson and Belshaw 2008). Most remarkable evidence to show nutritions influence 
on the epigenome of mammals came from studies with mice possessing the agouti 
viable yellow gene, with its normal funktion of confering the wild type coat colour. 
Dominant mutations in this gene have been discovered to cause coat colour change to 
yellow, together with systemic phenomena as obesity, non-insulin-dependent-diabetic 
like constitution and susceptibility to various types of cancer. Mutation in the agouti 
viable yellow mouse (Avy) bases on a intracisternal A particle (IAP) which is a retroviral 
insert, having been included into the DNA in an antisense orientation, directly 5´of the 
first coding exon of the gene. Methylation status of the 5´ long terminal repeat within 
the inserted IAP alters the gene expression. It is acting like a wild type allel in a 
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methylated state and when unmethylated, the gene is expressed ubiquitously leading 
to the full extend of the agouti syndrome. An intermediate state of methylation entails 
a speckeled appearence. Thus the coat colour stands for the methylation status of the 
allele (Wolff, Kodell et al. 1998). 
Researchers availed themselves of this model, 
showing that feeding a diet rich in methyl-
donors, as for example folic acid, to pregnant 
females can lead to alterations in the 
offspring`s agouti gene. There is good evi-
dence that this alteration is due to a change in 
the epigenetic state and might be passed to a 
consecutive generation via female germline. 
Even exposure to methyl donors in utero 
modifies epigenetic marks of developing germ 
cells. These modifications seem to be maintained through gametogenesis, fertilisation  
and embryonic development of the following generation (Johnson and Belshaw 2008).  
Food components, participating in the one-carbon metabolism, including vitamine B12, 
vitamine B6, folate and methionine provide methyl groups for the biochemical pathway 
of methylation processes. A carbon unit from serine or glycine is delivered to 
tetrahydrofolate to transfer it into 5,10-methylenetetrahydrofolate. Vitamin B6 is a 
transferenzymes co-facto. 5,10-methylenetetrahydrofolate is utilized to produce 
thymidine, formyltetrahydrofolate for purines and 5-methyltetrahydrofolate to 
methylate homocystein to form methionine, catalyzed by the vitamine B12 dependent 
enzyme methionine synthase. An ATP-dependant adenosylation of methionine 
generates S-adenosylmethionine (SAM), which is the methyl group donor for more 
than 80 biological methylations, inlcuding DNA, RNA and protein. A lack of dietary 
folate depletes plasma SAM pool, causing enhanced concentration of S-
adenosylhomocystein, as the equilibirum of the interconversion favors SAH synthesis, 
leading to SAH- level dependent inhibition of the DNA methyltransferase (Dolinoy, 
Weidman et al. 2006). 
 
 
Figure 5: Agouti mice 
                (Jirtle RL 2009) 
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 Figure 6: Folate metabolism, SAM supply  
                 (Miller, Borowsky et al. 2008) 
 
 
The SAM:SAH ration thus seems to be a limiting determinant for the transmethylation 
capacity of a system. Diminished dietary folate induced inhibition of DNA methylation 
appears to be associated with increased cancer susceptibility. Epidemiological data 
present, that low folate status is linked to higher risk in developing colorectal cancer, 
as tumor suppressor gene p53 or E-cadherine for instance also undergoe 
hypomethylation. Alkohol consumption affects folate metabolism and enhances 
cancer susceptibility in oral cavity, pharynx, esophagus and liver. DNMT mRNA levels in 
sperm were reported to be altered by chronic exposure to alcohol, therefore 
interrupting parental genomic imprinting. This effect is assumed to be responsible for 
paternal impact of alcohol on abnormal fetal development and growth (Davis and 
Uthus 2004).   
Polymorphisms in major DNA methylation regulating enzymes, mainly in the 
methylentetrahydrofolat reductase (MTHFR) gene, affect genome wide and gene 
specific DNA methylation. Most common gene variants are C677T, which has been 
associated with a reduced risk of developing colon cancer but an increased risk of 
developing  breast cancer and A1298C possessing  reduced enzyme activity that causes 
deficiency in methyl group donors (Johnson and Belshaw 2008). 
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Several more bioactive food components impacting DNA methylation, such as 
selenium, vitamin A and genistein, have been suggested to alter cancer susceptibility. 
High levels of retinoic acid and zinc deficiency induced DNA hypomethylation in rat 
livers, due to diminished utilisation of methyl groups from SAM (Davis and Uthus 2004). 
Selenium has been noted to correlate inversly with homocystein levels in humans 
eventually influencing methylation reactions through the SAM:SAH ratio and a 
deficiency induced hypomethylation has been observed in Caco-2 cells as well as in the 
liver and colon of rats. This might be due to direct interaction between the DNA 
methyltransferase and selenium, as increased selenium concentrations have been 
shown to suppress DNMT1 actvity and expression (Johnson and Belshaw 2008). 
Cadmium is an DNMT inhibitor as shown in animal studies. This effect is likely to be 
due to cadmium´s, and also zink´s propertie as a metal possibly binding to the cystein 
residue of the DNMT acitve center. All things considererd there might be an optimal 
level for dietary components contributing an unobstructed DNA methylation process, 
as for instance an absence as well as an excess of arsenic was demontsrated to entail 
global hypomethylation in rat liver (Davis and Uthus 2004). 
A diet rich in plant-derived foods conceals a variety of biologically active compounds 
also named phytochemicals, a large part of which are polypheols affect epigenetic 
modifications. Some of them, which were used in these experiments, are discribed 
below. 
An impressing example of how enviroment impacts epigenetic patterns was shown by 
Weaver et al. demonstrating how maternal care can affect DNA methylation state of 
the glucocorticoid receptor (GR) gene promoter in the hippocampus of the offsping.  
Ratmother´s nusing modified histone acetylation, DNA methylation and binding of the 
transcription factor NGFI-A to the GR promoter, altering its expression and hypo-
thalamic-pituitary-adrenal response to stress. This effect was shown for 900 further 
genes and these changes were modifiable with HDAC inhibitors or methyl donors 
(Weaver, Meaney et al. 2006).   
Nuclear receptor estrogen receptor alpha (ESR1) expression is associated with 
alterations in rats maternal behaviore. Enhanced ESR1 promoter methylation came 
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along with less licking and grooming, in comparison to low level methylation rats. 
Aging has been reported to have an elemantary impact on DNA methylation in several 
cell types. Studies conducted with monozygotic twins provide evidences, that the 
major contributors to these age related modifications on the epigenetic pattern are 
enviroment and lifestyle (Johnson and Belshaw 2008). Genomic DNA hypomethylation 
and gene specific promoter DNA hypermethylation, dependent on the type of tissue, is 
associated with aging. ESR1 hypermethylation has been shown to be altered in human 
colon, heart, vessels, and prostatate tissue. In aged human colonic mucosa ESR1 
expression was discovered to be diminished due to promoter hypermethylation, which 
is analogical to earliest epigenetic alterations predisposing to cancerogenesis. (Issa, 
Ottaviano et al. 1994).    
Many more genes responsible for tumor suppression, cell cycle regulation, apoptosis, 
detoxification and lipid metabolism have been shown to be affected by aging 
dependent promoter DNA methylation. Comparing young and old mice, p16INK4a 
promoter methylation enhanced concurrent with age and treatment with dietary 
folate. But p16INK4a was also found to be hypermethylated in aged human liver and 
stomach tissue (Kim, Friso et al. 2009).  
Different possible mechanisms have been proposed to be responsible for age – 
associated changes in genomic DNA methylation. DNMT1 declines continuously from 
birth to age, eventually leading to passive decreased doublication of methylation 
patterns during mitosis (Vertino, Issa et al. 1994). Furthermore aging implicates raised 
homocystein levels, which might cause disruption of methyltransfer as  S-adenosyl-
homocystein inhibits DNA methyltransferase (Yi, Melnyk et al. 2000).  Enhanced 
homocystein levels are associated with an age related decrease in sex hormones. 
Because of decreased folate intake and changed folate bioavailability folate status also 
declines during aging. Deficiency in zink and selenium might also contribute to DNA 
hypomethylation by modifing one carbone metabolism. Finally, unlike global 
hypomethylation due to decreased DNMT1 activity, gene specific promoter 
hypermethylation was detected during aging is possibly induced by enhanced de novo 
methylation through other DNMTs. DNMT3b for instance was found to be more active 
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in aged and immortalized cells. Another assumption is, that heterochromatine, being 
highly methylated, might spread to euchromatine over boundary elements by aging. 
However, aging processes have been suggested to not only be associated with DNA 
methylation, but other epigenetic phenomena of chromatin remodelling appears to 
also be involved (Kim, Friso et al. 2009). 
 
2.3 Examined genes and substances 
 
Gene selection based on studies suggesting, that two distinct types of promoter 
methylation occur in cancer cells. One is suggested to involve gene methylation in  
cells as a function of age (ESR1) and the second one mainly in neoplastic cells (p16INK4a 
and p15INK4b ) (Hinshelwood, Melki et al. 2009). Each of the three genes is involved in 
the regulation of the cell cycle through directly or indirectly influencing cyclin 
dependent kinases (CDKs) (Foster, Henley et al. 2001; Chim, Wong et al. 2003). 
 
2.3.1 The ESR1 gene 
The estrogen receptor alpha (ESR1) plays an important role in physiological processes 
but is also known to be involved in many pathologies as it regulates growth and 
differentiation of several tissue types. ESR1 appertains to the superfamily of nuclear 
receptors and family of steroid receptors, acting as a ligand- inducible transcription 
factor. Ligand bound ESR1 works as a key-transcription factor in various molecular 
pathways and adequate modulation of ESR1 expression is crucial to determine growth 
potential. A variety of hormones, growth factors and other agents implicate multiple 
cellular systems in the control or ESR1 expression (Pinzone, Stevenson et al. 2004). 
Estrogen has at least two courses of action. The nonclassical pathway of estrogen 
action leads to the activation of the MAPK (Mitogen-Activated Protein Kinase) cascade 
and other cell proliferating effects (Wong, McNally et al. 2002). The classical pathway 
depends on immediate interaction with its receptor, mediating gene transcription 
through binding palindromic ERE (Estrogen Response Elements) or interacting with 
transcription factors influencing their activity. ESR1 mediates cell cycle progression 
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through transcriptionally regulating estrogen-responsive genes, such as Cyclin-D1 
(Foster, Henley et al. 2001), a critical mitogen-regulated cell cycle control element, 
affecting activation of Rb (Retinoblastoma Protein) (Lamb, Ladha et al. 2000). 
 
        
 Figure 7: Estrogen receptor mechanism 
                (www.andrology.be) 
 
 
 
Approximately two-thirds of cases of breast cancers express ESR1 protein and with 
lacking  gene expression these cancers seldomly respond to endocrine therapy and are 
associated with worse clinical outcome. Hence deprivation of ESR1 gene expression 
leads to acquirement of  hormone resistance. ESR1 negative breast cancers show no 
significant genetic alterations in the ESR1 gene, such as insertion, deletion, 
rearrangement or point mutation. Loss of gene expression is currently explained by 
either epigenetic modifications or lack of trans-acting factors (Yoshida, Eguchi et al. 
2000). ESR1s expression is known to be epigenetically disregulated in several diseases 
comprising breast, prostatate and colon cancer but may also play a role in 
atherogenesis and development of heart disease (Post, Goldschmidt-Clermont et al. 
1999; Li, Shiina et al. 2004; Macaluso, Montanari et al. 2007), as it has been 
demonstrated to modulate expression of proteins involved in the regulation of plasma 
lipid metabolism, such as apolipoprotein E and LDL receptor (Klos, Boerwinkle et al. 
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2008). Variants (SNPs) of the ESR1 gene have been associated with components of the 
metabolic syndrome, including obesity, HDL-cholesterol, blood pressure and type 2 
diabetes (Gallagher, Langefeld et al. 2007). 
The ESR1 gene on chromosome 6q25 has a typical CpG island in its promoter and first 
exon that contains several methylation- sensitive restriction ezyme sites. In the ESR1 
promoter of normal, not neoplastic human colon mucosa, methylation of several CpG 
sites were found to be direrctly related to the age of examined individuals. Thus ESR1 
CpG island methylation arises as a direct funktion of age in normal colonic mucosa and 
is present in virtually all colonic neoplasias. In cultured colon cancer cells,  methylation 
dependent loss of ESR1 expression resulted in deregulated growth, linking CpG 
methylation during physiological aging to the development of neoplasia (Issa, 
Ottaviano et al. 1994). Similar results were found in vascular tissue with age 
dependent methylation associated inactivation of the ESR1 gene, propably playing a 
role in the aging of the vascular system and its consequences (Post, Goldschmidt-
Clermont et al. 1999). Estrogen is known to be neuroprotective. Ischemia induction in 
the cerebral cortex of female rats resulted in a repression of DNA methylation and 
MeCP2 adhesion in the ESR1 promoter. MECP2 usually interacts with the ESR1 gene to 
maintain methylation and suppress gene expression (Westberry, Prewitt et al. 2008).  
ESR1 silencing due to hypermethylation is associated with binding of specific methyl-
binding proteins, DMNTs and HDACs. Inhibition of HDAC  acitvity through Trichosatin A 
lead to an accumulation of hyperacetylated core histones. HDAC and DNMT inhibitors 
modulate histone methylation at K3-K9 and H3K4 to allow an open transcription active 
chromatine configuration needed for reactivation of silenced ESR1 transcription 
(Pinzone, Stevenson et al. 2004; Sharma, Blum et al. 2005). 
Trans active factors also seem to play an important role in the epigenetic modulation 
of ESR1. The presence of a specific pRb2/p130 multimulecular complex on the ESR1 
promoter strongly correlates  with the methylation status of this gene, eventually by 
cooperating with DNA methyltransferases in maintaining methylation patterns of the 
ESR1 gene (Macaluso, Montanari et al. 2007). 
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2.3.2 Tumor suppressor genes p16INK4a and p15INK4b    
The mammalian cell cycle system is controlled by CDKs, catalyzing the addition of 
phosphate groups to particular serines or threonines in order to alter protein´s 
attributes. CDKs are activated through subunits termed cyclins. During cell cycle the 
amount of CDKs persists at the same level whereas the number of cyclins oscillates. 
Reacting on antiproliferative and growth deprecating signals, CDKs associate with 
inhibitory subunits, CDK inhibitors (CDKi) (Chim, Wong et al. 2003).  
ESR1 contributes to cell cycle progression by inducing transcription of Cyclin –D1 
(Foster, Henley et al. 2001), a cell cycle control element, which  associates with CDK 4 
or CDK 6 (Lamb, Ladha et al. 2000). Among the group of the CDK - inhibitors are tumor 
suppressor genes p16INK4a and p15INK4b belonging to the INK4 family and specifically 
binding to CDK 4 and 6 leading to pause of cell cycle progression in the G1 phase. The 
INK family members share similar functional domains, ankyrin repeats for protein-
protein interactions, which allow them to compete with Cyclin D for CDK 4 and 6  
(Chim, Wong et al. 2003). 
In the setting of p16INK4a and p15INK4b   
inactivity, CDK 4/6 is able to couple with 
Cyclin D, leading to phosphorylation of Rb, 
which sequesters the transcription-factor 
E2F, stimulating entry into the S phase 
(Ishiguro, Takahata et al. 2006). 
Even though p16INK4a and p15INK4b are 
located close to each other on chromosome 9p21 and show high homology in the 
amino acid sequence, transcriptional activation systems were suggested to be different.  
P15INK4b induction during TGF-β triggered growth inhibition was reported to be 
associated with downregulation of protooncogen myc, whereas another study found 
p16INK4a transcription to be regulated by junB, a transcription factor inhibiting cell cycle 
progression. Moreover, induction of both p16INK4a and p15INK4b expression were 
reported to be modulated by the RAS/Raf/MEK/MAPK pathway in cell models. MAPK 
 
 
Figure 8: CDK-inhibitors  
                (Blagosklonny 2009) 
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members mediate cell prolifeation, stress response and growth suppression  due to a 
variety of agonists (Wen-Sheng 2003; Ishiguro, Takahata et al. 2006). 
P16INK4a and p15INK4b are known to undergo genetic alterations such as point mutations, 
deletions or loss of heterozygosity in the course of cancer development but also 
methylation dependent inactivation of the  p16INK4a promoter has been found in 
various neoplasias, such as colorectal, lung and breast carcinomas. P15INK4b is well 
documented in hematolocical malignangy, but less in solid tumors (Ishiguro, Takahata 
et al. 2006). 
Both tumor suppressor genes have a promoter and an exonic CpG island. In a study 
with several cancer tissues invariable hypermethylation of exon 2 has been detected 
for  either, p16INK4a and p15INK4b, whereas promoter methylation was specific for the 
cancer type. This might be explained by nonpromoter CpG islands to be somehow less 
protected against de novo methylation than those in the 5´region of a gene, maybe 
due to promoter CpG protection from DNA methyltransferases through steric 
hindrance by transcription-initiation complexes and various transcription factors. 
Differences in chromatine structure at exonic CpG islands could be another 
explanation. It has been demonstrated for instance, that suppression of poly 
(adenosine diphospate ribosyl-)ation of histone H1 induces de novo methylaton in 
transfected foreign DNA, inducing chromatin compaction and hypermethylation of 
endogenous islands (Nguyen, Liang et al. 2001). Several studies on hepatocellular 
carcinoma have demonstrated methylated p16INK4a and p15INK4b to be detectable in the 
patients serum at the time of cancer diagnosis. Accordingly, methylation of p16INK4a 
and p15INK4b could serve as an potentially valuable biomarker for early preclinical, 
modestly invasive detection of malignant lesions (Wong, Lo et al. 1999; Wong, Lo et al. 
2000). 
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2.3.3 Substances 
 
Since epigenetic modifications are potentially reversible, compared to genetic 
mutations, they display attractive targets for therapeutic or dietary support of 
pharmacological intervention.  
Substances used in this study are all bioactive food components or result of 
micobiobial processing, aside from zebularine, serving as a reference for DNA 
methylation inhibition. 
Folic acid 
Being a water soluble vitamine, folate is 
essential for numerous cellular processes. 5,10-
methylene-tetrahydrofolate can be trans-
formed to 10-formyltetrahydrofolate, which is 
a purine and it is necessary for the conversion 
of deoxyuridine to thymidylate for DNA 
synthesis and repair. Folate deficiency can 
cause uracil mis-incorporation and DNA repair 
mechanisms cut misplaced uracil, whithout having newly synthesized thymidylate for  
replacement. Thus DNA becomes fragile, provoking strand breaks. This predisposes to 
tumorigenic processes.  
Fundamental for epigenetic procedures is the conversion of 5,10 methylene-
tetrahydrofolate to  5-methyltetrahydrofolate. It is needed for the transfomation of 
homocysteine into methionine, since it serves as methyl donor. ATP therafter activates 
methionine to S-adenosylmethionine (SAM), which in turn is an universal methyl donor, 
dispensing methyl groups in a variety of reactions. Low SAM levels due to a lack of 
folate supply suppresses methylation reactions, including DNA and histone 
methylation (Miller, Borowsky et al. 2008). Effects of folate deficiency and 
supplementation on DNA methylation are gene and site specific and seem to depend 
on degree and duration of folate depletion, cell and tissue type and kind of organ (Kim 
2005). 
 
 
 
Figure 9: Folic acid structure 
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Genistein 
Genistein is a natural isoflavone found in 
soybean products. Incidence of breast and 
prostate cancer is significantly higher in the US 
or Europe than Asia. Researchers assume, that 
this might be due to different dietary patterns, 
with asians consuming a diet traditionally high 
in soy products. Supporting this supposition 
epidemiological studies detected an inverse association with the risk of developing 
benign fibrocystic conditions or different cancer types and comparatively high levels of 
soy isoflavone consumption.  
Due to genisteins hydrophobic property it is assumed to be taken up by cells not being 
processed and biologically activated before. Since genistein exhibits structural 
homology it competes with 17β-estradiol in estrogen receptor binding assays, 
therefore offering potential mechanism in the prevention of hormone related cancers. 
High plasma concentrations of genistein correlated with antimetastatic acitvity in vitro. 
Next to its anticancerogenic properties including increase of sensitivity of cancer cells 
to radiotherapy, chemotherapeutical and cytotoxic drugs, genistein lowers the 
incidence of cardiovascular diseases (Banerjee, Li et al. 2008). Thanks to genisteins 
antioxidative effect, it neutralizes free radicals, protecting cells against reactive oxygen 
induced expression of stress response related genes (Ruiz-Larrea, Mohan et al. 1997). 
Genistein inhibits protein-tyrosine kinase, a mediatior of growth factor effects. Also 
HER-2 protooncogene phosphorylation is inhibited by genistein leading to delayed 
HER-2 overexpressing tumor growth. Genisteins antiproliferative and proapoptotic 
properties might also be due to its ability to inhibit 5 alpha reductase and protein 
histidine kinase (Banerjee, Li et al. 2008). However there is growing evidence, that 
genistein might also be a risk factor under certain conditions, since recent reports 
suggest genistein to have genotoxic effects as it inhibits topoisomerase I and II , 
causing DNA breakage and genetic lesions, such as chromatid exchanges and 
chromosomal translocation in periperal lymphocytes (Kim, Yang et al. 2008).  
 
 
Figure 10: Genistein structure  
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Genistein is able to eventually induce apoptosis by preventing activation of nuclear 
factor 'kappa-light-chain-enhancer' of activated B-cells (NFkB) via AKT signaling 
mediation. Akt is a serine/threonine protein kinase and a crucial part of cellular 
survival pathway. It works downstream of phosphatidylinositol 3-kinase (PI3K) in 
response to mitogen or growth stimulation and its activation modulates the activity of 
several transcription factors such as fork head transcription factor (FOXO) and NFkB. 
FOXO proteins operate downstream of PTEN (phosphatase and tensin homolog) tumor 
suppressor, that was demonstrated to be induced by genistein and to negativley 
modulate Akt activity. NFkB is constitutionally activated in several tumor types and 
modulates gene expression of proliferative, apoptotic, inflammatory and immune 
response proteins. Sirtuines regulate the acitvity of several transcription factors and 
coregulators, like p53, NFkB, FOXO1, 3a and PPARγ. Genisteins epigenetic properties of 
cell growth inhibiton and apoptose induction seem to be due to inacitvation of the AKT-
pathway via inhibition of PI3K and increased mRNA levels of PTEN, tumor suppressor gene 
p53, and FOXO3a. NF-κB´s DNA-binding activity is decreased by inhibited nuclear 
translocation. SIRT1 expression decreased followed by enhanced histone acetylation of 
H3K9 in gene promoter regions of PTEN and FOXO3a, resulting in heightened gene 
expression (Kikuno, Shiina et al. 2008). 
Genistein was also reported to down-regulate telomerase activity by inhibtion of hTERT 
(human telomerase reverse transcriptase) transcription, which is the catalytic subunit of 
the human telomerase enzyme, contributing to apoptosis of cancer cells. Genistein is  
assumed to inhibit expression by epigenetic mechanisms as the three major DNA 
methyltransferases (DNMT1, 3a and 3b) were also decreased in genistein-treated cells 
and genistein induced chromatin structure remodeling of the hTERT promoter by 
increasing trimethyl-H3K9 but decreasing dimethyl-H3K4 (Li, Liu et al. 2009).  
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Butyrate  
Microbial metabolism of dietary fibers in the lower 
gastrointestinal tract generates butyrate, a short 
chain fatty acid. Butyrate has been reported to 
impart several health benefits including anti-
neoplasic properties (Davie 2003; Waldecker, 
Kautenburger et al. 2008). The effect of butyrate on epigenetic patterns of cancer cells 
seems to be twofold: Primarily butyrate possesses the ability to non specificly inhibit 
HDACs. Reactivation of tumor suppressor genes like p21Waf1/Cip1 (CDKN1A) and down-
regulation of Cyclin D, both playing an important role in the cell cycle, was reported be 
due to butyrate treatment, inducing growth arrest and apoptosis. This effect might 
additionally be modulated by butyrates effects on nonhistone proteins, such as 
transcription factors, or on noneuchromatic target (Rada-Iglesias, Enroth et al. 2007). 
Furthermore its ability to induce apoptosis might be due to pro-caspase-3 cleavage, 
transforming it into its active form whereas additional intermediate steps seem to be 
involved, as pharmacologically blockage of protein syntheses prevents butyrate from 
mediating apoptosis (Ruemmele, Dionne et al. 1999). 
Secondly, in addition to butyrates HDAC inhibitoring activity, it seems to reverse 
aberrant DNA methylation. But the mechanism by wich butyrate impairs DNA 
methylation patterns is presently unclear. Surprisingly, decrease in DNA methylation 
was independent of excessive DNA synthesis, although usually, in order to originate 
unmethylated DNA by DNMTs, a new strand needs to be synthesized. Thus butyrate 
seems to stimulate active demethylation. A feasible explanation for active promoter 
demethylation might be direct enzymatic removal of methylgroups from 5-
methylcytosines or excision and replacement of methylated cytosine through base 
excision repair mechanisms. The demethylating impact of butyrate only influences a  
limited number of loci but does not cause genome wide demethylation (Spurling, Suhl 
et al. 2008). 
Butyrates ability to influence DNA methylation patterns might be associated with its 
HDAC inhibition property, as CpG islands are significantly more frequent in 
 
 
   Figure 11: Butyrate structure 
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deacetylated regions, pointing towards a mechanistic link between DNA methylation 
and histone acetylation. Until today  the question whether deacetylation is the cause 
or consequence of gene silencing has not been resolved (Rada-Iglesias, Enroth et al. 
2007). Another explanation to this phenomenom might be existence of a butyrate 
response element in the promoter regions of the affected genes, representing only 2% 
of all mammalian genes. Trancription factors Sp and Sp3, located within butyrate 
response element binding sites, can activate or repress transcription. P21Waf1/Cip1 for 
instance contains six Sp1-binding sites (Davie 2003). 
Butyrates ability to modify the epigenetic program might be supported by a 
combination with another epigenetically active agent. A combination of butyrate with 
genistein caused a better gene reactivation than one agent alone  (Spurling, Suhl et al. 
2008). Similar to butyrate together with resveratrol, enhancing butyrate’s effect on the 
induction of p21Waf1/Cip  in Caco-2 cells (Wolter and Stein 2002).  
 
 
EGCG    
One of the major polyphenols found in green tea 
is Epigallocatechin-3-gallate. As EGCG is able to 
inhibit cancer cell growth, induce apoptosis and 
suppress tumor angiogenesis, it presumably 
mediates its antitumorigenic properites via 
several different transactions (Berletch, Liu et al. 
2008): Beside its antioxidant, radical scavenging 
property, EGCG was found to have an anti NF-kB 
transactivation activity in a broad range of human 
malignancies, for instance in colon and breast cancer, as well as in chronic 
inflammation. Blockage of NFkB signal transduction pathway by EGCG leads to 
suppression of nitric oxide synthase (NOS2) production, which plays a role in cancer 
development.  
 
 
 Figure 12: EGCG structure 
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EGCG exhibits efficient anti-HAT activity, showing global specificity for the majority of 
HAT enzymes, eventually representing the mechanism of NFkB inhibition. EGCG-
induced hypoacetylation of p65, a subunit of NF-kB, might cause an exchange between 
HDACs and HATs in the promoter region of a NF-kB– regulated genes (Choi, Jung et al. 
2009). 
EGCG treatment was shown to ablate histone acetylation and decrease promoter 
methylation in the hTERT promoter, whereas an increased promoter binding of E2F-1, 
a hTERT repressor, could be detected. This lead to dimished cell proliferation and 
provoked apoptosis. The decrease in promoter methylation might be due to inhibition 
of DNMT1 (Berletch, Liu et al. 2008), as SAM methylates EGCG on two methylation 
sites and therefore is converted into SAH. With SAM being substrate of DNMTs EGCG 
inhibits DNMT1 competitivley, leading to an decease in DNA methylation (Fang, Chen 
et al. 2007).  
 
 
Resveratrol 
Epidemiological studies in the early 1970´s, correlated 
red wine consumption with decreased appearance of 
cardiovascular disease and so created the `frech 
paradox´, which was resolved with the identification 
of antioxidants such as resveratrol, which is mainly 
present in grape skin and peanuts. Resveratrol was 
found to interact with lipoproteins, decrease 
oxidation of low density lipoproteins (LDL) and inhibit 
platelet aggregation as well as polymorphonuclear cell activation, which are known to 
generate reactive oxygen species. Additionally, resveratrol induces vasorelaxation and 
impaired expression of adhesion molecules, thus decreasing thrombogenic potential 
(Signorelli and Ghidoni 2005).  
Resveratrol has been suggested to be a potential calorie restriction mimetic. It slows 
aging by promoting conformational changes and therefore activate sirtuins, especially 
SIRT 1 (Borra, Smith et al. 2005). A recent study showed resveratrol to stimulate 
 
 
      Figure 13: Resveratrol structure 
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mitochondrial function and to obviate metabolic disorders in mice, which were fed a 
high-fat diet. This effect was mediated by SIRT1-dependent activation of PGC1α, a key 
regulator of energy metabolism (Delage and Dashwood 2008). 
Resveratrol can be considered a selecive estrogen modulator, positivley influencing 
estrogen receptor expressing and non expressing human tumors, as it is similar to 
synthetic estrogen diethylsilbestrol, activating hormone receptor mediated gene 
expression. In contrast to its estrogenic properties it also displays an antiestrogenic 
effect via triggering pathways that inhibit estrogen mediated outcomes like 
proliferation, tumor transfomation and progression. Binding to Erβ, it inhibits 
expression of ESR1 and regulates androgen receptor (Signorelli and Ghidoni 2005).  
Resveratrols  antineoplastic properties base on blocking three stages of carcinogenesis: 
initation, promotion and progression. It participates in the regulation of proteins 
responsible for DNA synthesis and cell cycle, such as p53 and Rb/E2F, cyclins, cyclin-
dependent kinases (CDKs) and their inhibitors. Furthermore, resveratrol affects the 
activity of transcriptional factors influencing proliferation and stress responses, such as 
NF-kB and AP1. These processes might be mediated by mitogen-activated protein 
kinases (MAPKs) and tyrosine kinases, entailing the modulation of survival and 
apoptotic factors as well as enzymes involved in carcinogenesis such as 
cyclooxygenases (COXs), nitric oxide synthase (NOS) and phase I and II enzymes 
(Signorelli and Ghidoni 2005).  
Activated SIRT1 mediates RelA/p54 deacetylation, inhibiting TNF α- induced NF-kB 
transcription and sensitizing cells to apoptosis (Yeung, Hoberg et al. 2004), whereas 
SIRT 1 also deacetylates and inactivates p53 in a balanced equilibrium with the actions 
of HDAC1 eventually blocking apoptosis and promoting cell survival. Expression of    
NF-kB and p53 activating acetyltransferase p300 can also be increased by resveratrol. 
Other studies found out, that resveratrol does not inhibit but increase TNF α induction 
of NFkB due to SIRT1s pharmacological blockage, in contrast SIRT1 overexpression 
inverts activation of NFkB, possibly mediated by p300. Thus, resveratrol modulates the 
two gene transcription factors p300 and SIRT1, triggering opposite pathways of 
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apoptosis and proliferation, with p300 acivating and SIRT1 inhibiting proliferative NFkB 
and apoptotic p53 (Signorelli and Ghidoni 2005). 
 
Zebularine   
Zebularine serves as a reference DNMT inhibitor in this 
study. Originally synthesized as a cytidine deaminase 
inhibitor, zebularine structurally corresponds to 
cytidine and was found to be a potent inhibitor of DNA 
cytosine methyltransferase. These findings promote 
zebularine to be a auspicious anticancer agent as it 
preferetially targets tumorigenic cells. Since its mRNA 
seems to be unaffected in a study with LD419 
fibroblasts, DNMT inhibiton seems to function on protein level by covalent complexing 
of the DNMT enzymes (Billam, Sobolewski et al. 2009). DMNT1, being mainly 
associated with maintenance methylation, seems to be primarily affected, followed by 
DMNT3b and DNMT3a. Zebularine was found to function in vitro and in experimental 
animal studies after oral application. Clinical trials were already conducted, mainly on 
acute leukemias and myelodisplasia. As mentioned above, two further drugs acting in a 
similar way, 5- azacytidine and 5-aza-2´deoxycytidine were found to inhibit DNA 
methylation but are unfortunately limited due to their instability. Zebularine, on the 
other hand, is highly stable at neutral pH- and nontoxic in adequate doses. Gene 
silencing by DNA remethylation of tumor suppressor genes is a conversant issue for 
demethylating drugs, requiring a constant application. Due to its minimal cytotoxicity, 
zebularine can be given uninterrupted in low doses over a longer period to provide 
continous demethylation. As shown in human bladder tumor cells, zebularine caused 
de-methylation as well as reactivation of a hypermethylated promoter and therefore 
silenced p16INK4a and p15INK4b in an AML cell line (Yoo, Cheng et al. 2004; Marquez, 
Kelley et al. 2005). 
 
 
  Figure 14: Zebularine structure 
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3 OBJECTIVES 
The nuclear hormone receptor estrogen receptor α (ESR1) stimulates cellular growth 
through ligand-dependent induction of genes involved in cell proliferation, possibly 
leading to carcinogenesis. Moreover, ESR1 plays a role in the development of 
arthereosclerosis, as it impacts plasmalipid levels and certain ESR1 SNPs seem to be 
associated with the metabolic syndrome and obesity. The tumor suppressor proteins 
p16INK4a and p15INK4b (the INK4 proteins) participate in the regulation of the 
mammalian cell division cycle to ensure balanced cell proliferation and are frequently 
inactivated in human cancers. Numerous studies have shown ESR1, p16INK4a and 
p15INK4b to be regulated epigenetically via DNA CpG promoter methylation. Unlike 
many other genomic alterations that occur during carcinogenesis, DNA methylation is 
potentially reversible via the use of preventive or therapeutic agents. A multitude of 
bioactive food components have been detected to epigenetically impact the 
methylation state of genes involved in the pathways of complex diseases. To correlate 
hormonal and epigenetic activities of selected bioactive food components we analyzed 
the effect of butyrate, resveratrol, genistein, EGCG, folic acid and reference DNMT 
inhibitor zebularine on the promoter methylation state of ESR1, p16INK4a and p15INK4b  in 
Caco-2 cells. Results of this study should contribute to the insight how food 
components might interfere with hormonal signaling and epigenetic pathways of 
cancer development.  
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4 MATERIALS AND METHODS 
 
4.1 Cell culture conditions and treatment 
 
For this essay the human Caco-2 cell line, an immortalized line of heterogeneous 
epithelial colorectal adenocarcinoma cells (Shah, Jogani et al. 2006), were grown at 
37°C in a humidified atmosphere (5% CO2), in six well tissue culture plates and 
cultured in RPIM 1640 media, supplemented with 10% heat inactivated fetal bovine 
serum, 4mM glutamine and 100 units of streptomycin and penicillin respectively. Cells 
mature as confluent monolayer and a 48-h treatment was carried out after exactly 2 
weeks of cell gowth. Cell treatments were performed in dublicates and pooled for the 
analysis. Table 1  lists agents and agent´s concentration used for the cell treatment.  
Cells were washed twice with cooled PBS (4°C) before nucleotide extraction. 
 
                                    
 
Substance Concentration 
Zebularine 100 μmol/l 
Folic acid 200 μmol/l 
Genistein 200 μmol/l 
EGCG 200 μmol/l 
Butyrate  200 μmol/l 
Resveratrol 10 μmol/l 
  Table 1: Substances and concentrations of cell treatment  
 
 
 
4.2 PCR and real time PCR  
 
Principle of PCR 
Principle of Polymerase chain reaction (PCR) is to amplify small regions of a single or 
double stranded DNA by an enzymatic reaction. Specific parts of the original DNA 
molecule are replicated by a DNA polymerase enzyme, doubling the number of DNA 
molecules.  
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Following components are required for the reaction:   
• Deoxy-nucleotidetriphophats (dNTPs), for synthesizing new DNA fragments  
• DNA-Polymerase enzyme (Taq polymerase) from Thermus aquaticus 
• Buffer and MgCl2, serving as polymerase cofaktor   
• Primers, being short oligonucleotides reqired as start signal for the DNA-
Polymerase  
• Fluorescent reporter for detection  (only in real time PCR)  
 
A three-step reaction exponentially increases the amount of DNA fragments :  
The reaction is performed by temperature cycling. High temperatures (90°C to 95°) are 
needed to separate strands of the DNA double helix (Denaturation) then temperature 
is lowered (50°C to 70°C) to let primers bind to the template (Annealing) and finally 
the temperature is set to the enzyms optimum (72°C), building the DNA strand by 
extending primers through dNTPs incorporation (Elongation).  
 
 
 
 Figure 15:  PCR temperature cycle   
 
 
For one PCR run usually 30 to 40 cycles of denaturation, annealing and elongation are 
conducted. For optimal reaction conditions concentration of MgCl2, which builds 
complexes with dNTPs and stables primer annealing on the template, should be 
approximately 1,5 mM and of deoxynucleotides approximately 400 μM. Primer 
concentration between 0.1 μM and 1 μM of each primer, depending on DNA target 
lentgh are needed.  
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Reqired degradation temperature and duration can change with length and sequence, 
as a G-C base pair contains three hydrogen bonds being more stable than an A-T base 
pair with only two hydrogen bonds.  
Anneling temperature is based upon primer-constitution. It should be some degrees 
lower than than melting temperature of the two primers. Primers should have a length 
beween 18 and 30 nucleotides and be designed to have similar melting temperatures, 
not build self or cross dimers, hairpins or other secondary structures. GC content 
should be between 40 and 60%. Self annealing can be prevented by choosing primers 
that are not complementary especially at the 3´ends.   
Primer melting temperature depends on DNA-DNA hybrid stability and is critical in 
determining temperture for the annealing (Ta). Too high Ta will produce low PCR yield 
because of insufficient primer-template hybridization, whereby too low Ta may 
possibly cause non-specific products through a high number of mismatched base pairs. 
Mismatch tolerance has the strongest effect on impact on PCR specificity, followed by 
primer length, template size and product size limit. 
Calculation of annealing temperature :  
Ta = 0.3 x Tm(primer) + 0.7 Tm (product) – 14.9   
Tm(primer) = Melting Temperature of the primers,   
Tm(product) = Melting temperature of the product   (Rychlik, Spencer et al. 1990) 
 
 
The amount of DNA copies is doubled during each cycle and can be formulated as 
follows:  
 
N = N0 x 2
n 
 
N  : number of DNA copies  
N0 : initial number of DNA-molecules  
n  : number of cycles  
2  : optimal efficiency (every cycle 2 DNA molecules result  
      out of one) 
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Real time PCR  
Real time PCR technique is able to monitor the progress of a PCR reaction in real time, 
thus continous visualization of PCR amplification during every phase of the reaction is 
given compared to traditional end-point PCR using agarose gel after completion of PCR 
cycles to detect amplification outcome and product quantity.  
Minimal amounts of nucleic acid are quantifiable, the technique is resource and time 
saving, very sensitive, reproducible and specific. The real time technique allows  
melting point analysis and mutltiplex PCR, enabling simultaneous amplification of 
many targets of interest in one reaction by using more than one pair of primers and 
detection systems.  
Detection is based on increasing fluorescence signals, emitted by a reporter molecule, 
as the reaction proceeds. Fluorescent reporter molecules include dyes attaching to 
double-stranded DNA or sequence specific probes. 
For the visualisation and quantitation of the reaction several real time PCR detection 
systems are available according to different requirements: 
 
DNA-binding agents:  DNA-binding agents like SYBR® Green which was utilized in this 
study, are double-stranded DNA binding dyes, to detect PCR product as it accumulates 
during PCR cycles. The resulting DNA-dye-complex emits a fluorescence signal. As 
more double stranded amplicons are produced in the elongation phase fluorescence 
signal multiplies.   
 
Hydrolysis probe technique (Taq man®):  This systems uses a hydrolysis probe, which 
exploits 5´exonuclease acitvity of polymerases, that cleaves a labeled hybridization probe 
during extension phase of the PCR. At 3´and 5´ ends, probe is marked with a fluorescent 
dye (fluorochrome) and a quencher. The probe is desigend to anneal the single stranded 
DNA between the two primers. The quencher absorbs fluorescence signal as long as the 
probe is not cleaved. During elongation phase the probe is cleaved due to polymerases 
exonuclease activity. As fluorochrome and the quencher get separated the 
fluorescence can be detected. 
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Hybridization probe technique (molecular beacons) : Two probes are required for this 
system, one labeled with donor fluorochrome binding nearby the second probe, which 
is labeled with acceptor fluorochrome. With both probes annealing to the DNA, the 
emitted light of the donor will excite the acceptor emitting a  fluorescence signal (FRET) 
which can be detected during the annealing and early elongation phase. 
After PCR amplification, real time machine can be programmed to perform a melt 
curve, in which the temperature is raised by a fraction of a degree and changes  in 
fluorescence- signal is measured. (Derivative of fluorescence with respect to tempe-
rature-dF/dT; temperature-deg). At the melting point, double stranded DNA separates 
and the signal  rapidly decreases. Primer-dimer artifact would give an additional peak 
with lower melting temperature.  
 
 Figure 16: Real time PCR amplification curves for two products   
 
 
    Figure 17: Real time PCR melt curves for two products   
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4.3 Gene expression quantification 
 
Principle of gene expression detection  
Messenger RNA as a inerstage of gene expression was extracted, converted into cDNA 
by reverse trancriptase reaction  and quantified by real time PCR. 
 
Procedure  
mRNA extration: NucleoSpin RNA 2-Kit (Marcherey-Nagel) was applied according to 
manufactures instruction (protocol attached).  
reverse transription: To convert mRNA into more stable cDNA, Transcriptor First Strand 
cDNA Synthesis Kit (Roche Diagnostics) was applied. 
 
Reaction mixes were compiled as follows:  
 
•       reverse transcriptase reaction buffer        4 μl  
•  deoxynucleotide mix                                    2 μl 
•  protector RNase inhibitor                        0,5 μl 
•  anchored-oligo (Post, Goldschmidt-Clermont et al.)18 primer                    1 μl 
•        reverse transcriptase                                0.5 μl  
•  water                                                              6 μl 
•  RNA                                                                 6 μl 
            total volume                                                  20 μl 
 
 
Mixes were heated up to 50°C for 60 minutes to perform the transcription then  
samples were exposed to  85°C for 5 minutes for transcriptase inactivation.  
 
Besides the anchored-oligo (Post, Goldschmidt-Clermont et al.) primers, consisting 
only of thymine bases and binding to the poly-A-tail of mRNAs, random hexamer 
primers, small primers of six base pairs, binding randomly to all mRNAs in the sample, 
or sequence specific primers which only allow transciption of specific genes or gen 
parts to be converted during reaction, can be used for the reverse transcription.  
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real time PCR: Primer sequences, reaction mixture composition and cycle condition 
were perfomed as listed below:  
 
 
Primer Sequence Annealing temp Concentration 
ESR1 se 5´- TGG GCT TAC TGA CCA ACC TG -3´ 60°C 5pmol/μl 
ESR1 as 5´- CCT GAT CAT GGA GGG TCA AA -3´ 60°C 5pmol/μl 
 
 
Table 2: Primer conditions for ESR1 gene expression 
 
 
 
Component Volume 
Sensi Mix 5μl 
Primer 1μl 
Sybr Green 0,2μl 
Water 2,8μl 
DNA 1μl 
Total Volume 10μl  
             Table 3: Components and volumes of reaction mixture for ESR1 gene expression  
 
 
Polymerase activation 10 min 95°C 
Cycling 35 times 
Denaturation 45 sec 95°C 
Annealing 60 sec 66°C 
Elongation 60 sec 72°C 
Melt curve 0,5°C every 5 sec 50°C - 95°C  
   Table 4: Cycling conditions for ESR1 gene expression  
 
 
4.4 DNA methylation detection    
 
Principle of DNA methylation detection  
Total genomic DNA was extracted from the cells. The bisulfit conversion reaction is 
based on the reaction of bisulifite with cytosine in single stranded DNA which, in an 
aqueus milieu, are converted to uracil, whereas 5- methylcytosine remains unreacitve.  
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The modified DNA strands, now low in C content are amplified by the use of PCR  
amplification. To increase specifity for this experiments nested PCR was used to 
amplify converted DNA within two steps. For final detection bisulfit genomic 
sequencing (BSP) or methylation specific PCR (MSP) can be used. 
 
Bisulfit sequencing PCR (BSP) 
Bisulfite genomic sequencing is the method of choice for the production of   
methylation maps with single-base resolution. The method contains selective 
deamination of cytosine to uracil by treatment with bisulfite and the subsequent 
purification and sequencing of generated PCR products. In contrast to cytosine, 5-
methylcytosine does not react with bisulfite and can therefore be distinguished, 
implying a C in CpG-site of interest interesting meaning that the C was methylated, 
whereas a  T used to be a fomer unmethylated CpG.  
 
Methylation specific PCR  (MSP)  
MSP entails initial modification of DNA by bisulfit conversion and subsequent 
amplification of the target DNA sequence by two sets of primers matching specificly 
for either methylated or unmethylated DNA .  
 
Procedure  
DNA extration: QIAamp DNA Mini Kit from Qiagen was applied according to 
manufactures instruction (protocol attached).  
 
 
 
          Figure 18: Bisulfite conversion  
                          (Hayatsu 2008) 
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Bisulfit conversion: EpiTect Bisulfite Kit from Qiagen was applied according to 
manufactures instruction (protocol attached). 
 
Methylation specific PCR: To increase specifity of MSP often nested PCR approaches 
are used. Nested PCR reduces contaminations in PCR products due to amplification of 
unintended primer binding.  
Two sets of primers are used in two successive PCR runs. The second set intends to 
amplify a secondary target within the first run product. Step one external primer flanke 
the CpG- rich promoter region of the target gene and thus do not discriminate 
between methylated and unmethylated CpGs due to bisulfit treatment. First step was 
perfomed by conventional end point PCR and correct amplification was verified by 
agarose gel electrophoresis and gel red detection using 300-nm transillumination.  
First step PCR products were diluted 1:1000 and subjected to second, internal MSP 
utilizing real time PCR and a set of two primer pairs, designed to distinguish bisulfite-
induced modifications of unmethylated from methylated cytosines. 
Primer conditions, reaction mixture composition and cycle condition were perfomed as 
listed below: 
 
 sense antisense Ann.temp 
External       
ESR1  GGYGAGGTGTATTTGGATAGTAGTAAGT CRAACTCRAAAACACRCTATTAAATAAA 58°C 
p15
INK4b 
 GAYGTYGGTTTTTTGGTTTAGTTGA AACRCAACCRAACTCAAAACC 55°C 
p16
INK4a
 AGAAAGAGGAGGGGTTGGTTGG ACRCCCRCACCTCCTCTACC 55°C 
Internal Unme      
ESR1  TGTTGTTTATGAGTTTAATGTTGTGGTT AAAAAAACCCCCCAAACCATT 58°C 
p15
INK4b 
 GGTTGGTTTTTTATTTTGTTAGAGTGAGG AACCACTCTAACCACAAAATACAAACAC 58°C 
p16
INK4a
 TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA 58°C 
Internal Me      
ESR1  ACGAGTTTAACGTCGCGGTC ACCCCCCAAACCGTTAAAAC 58°C 
p15
INK4b 
 GGTTTTTTATTTTGTTAGAGCGAGGC TAACCGCAAAATACGAACGCG 58°C 
p16
INK4a
 TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 58°C  
 Table 5: Primer conditions for ESR1, p15INK4b, p16INK4a MSP   
                         Primer concentration:  5pmol/μl                                              
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 External PCR Internal PCR 
Mastermix / Sensimix 25μl 5μl 
Primer 5μl 1μl 
SybrGreen / 0,2μl 
Water 15μl 3μl 
DNA 5μl 1μl 
Total volume 50μl 10μl  
  Table 6: Components and volumes of reaction mixture for MSP, external and internal PCR   
 
 
 
  External p16/p15 External ESR1 
Polymerase activation  10 min 95°C 
Cycling  30 times 
Annealing 60 sec 55°C 58°C 
Elongation 50 sec 72°C 
Melt curve  0,5°C every 5 sec 50°C - 95°C  
 Table 7: Cycling conditions for MSP, external and internal PCR   
 
 
4.5 Data analysis  
 
Real-time PCR runs were analyzed with the Rotor-Gene Version 6.1 software belonging 
to the Corbett Rotor Gene 300 real time cycler. Results were evaluated by comparative 
quantitation of the Rotor Gene software. Analyse was based on fluorescence history of 
the reactions. The software uses a second derivative of raw amplification data and 
determines take off points of the reactions. The slope of the line from take off point 
until exponential amplification stops is used to calculate amplification efficiency. 
Hypothetical concentrations were calculated and amplification efficiency was adjusted 
between individual samples. Gene expression was normalized to GAPDH as a reference 
gene, which was found to be stable expressed after cell treatments and gene 
expression as well as methylation results were calibrated relative to untreated cells as 
a control. Results were expressed in ratios. Average and the standard deviations were 
calculated with Microsoft Office Excel 2007. An F-test for homogeneity of variances 
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and a two tails t-test to determine the significance of the results were used. Results 
were regarded as significantly different at p<0.05. 
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5 RESULTS 
5.1 ESR1 gene expression and promoter methylation   
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  Figure 19: ESR1 gene expression and promoter methylation 
                    after 48h treatment with zebularine (Zeb), folic acid(FA), genistein (Gen),                           
                    epigallocatechin-3- gallate (EGCG), resveratrol (Res) and butyrate (But) 
 
 
 
Untreated Caco- 2 cells are predominantly methylated at the ESR1 pomoter site in a 
56:1 ratio. A distinct effect on ESR1´s promoter region methylation has been detected 
after cell treatment with genistein, causing a clear 2,84-fold ± 0,2 (p≤ 0,05) 
hypermethylation compared to untreated cells, whereas nearly no change in mRNA 
expression could be seen. Treatment with methyl donor folic acid results in an almost 
doubled ESR1´s promoter methylation grade, 1,96-fold ± 0,05 (p≤ 0,01) correlating 
with decreased (0,85 ± 0,57) but no significant decrease in gene expression. A clear 
2,03-fold ± 0,07 (p≤ 0,05) hypermethylation was also observed after cell exposure to 
EGCG and a slight but not significant decrease in gene expression could be seen (0,65 ± 
0,02). Treatment with butyrate caused a diminished ESR1 expression (0,91 ± 0,15) and 
a significant decrease in methylation (0,48 ± 0,05; p≤ 0,05). Resveratrol marginally 
impacts ESR1 and p16INK4a promoter methylation and only a slight (1,25± 0,36) but not 
significant increase in ESR1 mRNA expression could be detected. Methyltransferase 
inhibitor zebularine distinctively diminished methylation in ESR1, p16INK4a and p15INK4b . 
 RESULTS 49
Methylation at the ESR1 promoter site decreased significantly, 0,16 ± 0,01 (p≤ 0,01) 
but no significant change in mRNA expression (0,86 ± 0,20) could be observed.   
 
5.2 p16INK4a and p15INK4b promoter methylation  
 
 
     Figure 20: p15(INK4b) and p16 (INK4a) promoter methylation  
                        after 48h treatment with zebularine (Zeb), folic acid(FA), genistein (Gen),  
                        epigallo-catechin-3-gallate(EGCG), resveratrol (Res) and butyrate (But)  
 
 
 
In untreated cells p16INK4a CpG rich promoter site is predominantly methylated in 
contrast to the p15INK4b promoter, that was found to be regularily unmethylated: the 
comparison methylated versus unmethylated DNA showed a ratio of 5,00E-03 for 
p15INK4b gene and 8,29 E03 for p16INK4a. 
Treatment with genistein caused a 1,24 fold ± 0,18 hypermethylation in the p15INK4b 
promoter site compared to untreated cells. In contrast p16INK4a promoter was found to 
be nearly completely demethylated. Exposure to folic acid enhanced p16INK4a 
methylation 1,66-fold ± 0,40 and also p15INK4b methylation grade but not as clearly as 
for p16INK4a, 1,21 fold ± 0,27. EGCG treatment caused a significant reduction of p15INK4b 
(0,60 ± 0,01) (p≤ 0,05) and a slight decrease in p16INK4a (0,86 ± 0,41) promoter 
methylation. Exposure to butyrate significantly diminished both, p16INK4a  and p15INK4b 
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methylation state 6,92E-02 ± 0,04 (p≤ 0,05) and 0,57 ± 0,01 (p≤ 0,01) compared to 
untreated cells. Resveratrol had almoust no effect on p16INK4a promoter methylation 
but reduced methylation of p15INK4b : 0,62  ± 0,03 (p≤ 0,01). Reference DNMT inhibitor 
zebularine explicitly diminished methylation in the p16INK4a and p15INK4b promoter 
region: 6,74E-03 ± 0,01 (p≤ 0,05) and 0,64± 0,02 (p≤ 0,01). 
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6 DISCUSSION 
6.1 Methods   
As the Caco-2 cell displays characteristics of mature enterocytes (Sambuy, De Angelis 
et al. 2005), this study appears to be a good model for estimating the direct epigenetic 
impact of bioactive food components on the intestine. For the incubation agent 
concentrations were selected assumed to have an impact on cells epigenetic 
machinery. As this study was conducted using only one concentration and durance of 
each substance, different extends of impact due to higher or lower concentrations or 
treatment duration were not assessed. Further studies with this bioactive food 
components should comprise different concentrations and incubation durances as well 
as combinations of DNMT ihibitors and histone modifying agents including subseqent 
detection of histone modifications. Furthermore, global DNA methylation should be 
assessed to estimate the impact of a substance on the complete methylation state. A 
good approach would be to estimate substances concentrations in normal diet and to 
compare them to concentrations actually having an impact on the epigenetic pattern.  
 
6.2 ESR1 gene expression and promoter methylation   
 
The nuclear receptor ESR1 functions as a transcription factor upon hormonal signals, 
enhancing the transcription of genes involved in the regulation of cell growth. 
Epigenetic disregulation of ESR1 expression and concurrent alterations in the 
integration of hormonal signaling has been associated with the development of several 
diseases, such as the metabolic syndrome and cancer.  
Our results show untreated cells to be predominantly methylated at the ESR1 
promoter site. Caco-2 cells are derived from human epithelial colorectal carcinoma 
cells. These results are in agreement with studies describing human adenomatous and 
colon cancer tissue to be hypermethylated at the ESR1 promoter site (Issa, Ottaviano 
et al. 1994; Hinshelwood, Melki et al. 2009). Methylation patterns of free DNA, found 
in the buffy coat of patients with several cancer types, coincide with that of cancer 
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suppressor genes in the tumors (Feng, Hu et al. 2009). In contrast to Caco-2 cells, 
methylation state of ESR1 promoter region in 13 healthy women’s buffy coat DNA 
turned out to be nearly completely unmethylated (data not shown). These 
discrepancies in the methylation state in different tissues need to be considered in the 
evaluation of effects bioacitve food components have on methylation or de-
methylation, as the original methylation state of the promoter seems to impact the 
degree of treatment induced methylation changes (quod vide results: p15INK4a ). 
An elevated methylation level of the ESR1 promotor region after Caco-2 cells’ exposure 
to folic acid correlated with a reduced gene expression. These findings support 
preliminary studies suggesting that the rate of ESR1 methylation in colonic tissue is 
modifiable by dietary folate (Belshaw, Elliott et al. 2005). Zhu and Williams 
hypothesized that development of ER-negative breast cancers, which  are unsensitive 
to hormonal therapy, might result from methylation dependant inactivation of ESR1 
transcription due to methyl deficient diets (Zhu and Williams 1998). Proving that 
hypothesis an epidemiological study associated higher folate intake with reduced risk 
of developing ER-negative breast cancer, assuming that adequate folate intake is 
particularly important for women with higher risk potential (Zhang, Hankinson et al. 
2005).  
Genistein regulates ESR1 gene expression in a very complex way, amongst others due 
to its estrogenic, epigenetic (Hong, Nakagawa et al. 2004) and tyrosine kinase 
inhibiting (Li, Liu et al. 2009) properties. Although promoter methylation increased 
after treatment, we observed an enhanced expression of ESR1. This might be due to a 
lowered HDAC SIRT1 expression, increasing histone acetylation of H3K9 in several gene 
promoter regions accompanied by changes in methylation state (Kikuno, Shiina et al. 
2008). Similar observerations for genistein are being analyzed for IL-8 and will be 
presented elsewhere.  
EGCG treatment caused, in contrast to results for p15INK4a and p16INK4a, a twofold 
enhanced methylation of ESR1 promoter region and a correlating gene expression 
reduction by half. As EGCG was shown to be cancer cell growth inhibiting, these results 
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seem to be conclusive as p15INK4a and p16INK4a are cell cycle modulators and ESR1, 
activated by growth factors, acts as a potent mitogen for epithelial cells. 
Butyrate has been proven to induce histone acetylation by inhibiting histone 
deacetylases, as well as growth arrest or apoptosis (Delage and Dashwood 2008). We 
detected a slight decrease in ESR1 expression after treatment with butyrate, as 
previously shown in breast cancer cells (deFazio, Chiew et al. 1992), accompanied by 
clearly diminished methylation. CpG islands are significantly more common in 
deacetylated regions. This finding points towards a mechanistic link between DNA 
methylation and histone acetylation although it is not yet clear if histone deacetylation 
is the reason or the consequence of gene silencing. It might also be possible that these 
epigenetic alterations are responses to stress caused by butyrate treatment (Rada-
Iglesias, Enroth et al. 2007). Resveratrol, acting as a selective estrogen receptor 
modulator and modulator of SIRT1 HDAC activity, does seem to neither significantly 
affect methylation nor gene expression of ESR1. Studies working with Caco-2 cells 
investigated global DNA methylation after resveratrol treatment and obtained similar 
results. In this study only one concentration of 10 μmol/l and an incubation time of 
48h were used. In contrast, investigations on ER-positive breast cancer cells showed 
resveratrol to induce methylation changes in a variety of CpG islands after treatment 
with 50 μmol/l for 36 hours (Wenyi Qin 2005).  
Although exposure to well established reference DMNT inhibitor zebularine caused a 
virtually complete demethylation of the ESR1 promoter, almoust no effect on gene 
expression except for a slight decrease could be noted. As gene expression of ESR1 in 
this study does not always correlate with its promoter methylation state after 
treatment, expression could rather be influenced by CpG islands within exons of the 
gene or other epigenetic mechanisms, as shown by Zhou et al. They demonstrated 
reactivation of ESR1 gene by HDAC inhibitors to be whithout alteration in promoter 
DNA hypermethylation, suggesting expression of ESR1 to be regulated by histone 
modification or by a combination of DNA methylation and histone modifications (Zhou, 
Shaw et al. 2009). A recent study shows most methylation alterations in colon cancer 
to occur not in promoter regions but 2kb distant, which are termed “CpG island 
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shores”. Methylation of these DNA sites was strongly related to gene expression 
(Irizarry, Ladd-Acosta et al. 2009). Moreover regulation of ESR1 also comprises trans–
active factors such as TFAP2C inducing ESR1 transcription through an AP-2 regulatory 
region in the ESR1 promoter. Epigenetic chromatin modification could faciliate 
admission of trans active factors influencing gene transcription (Woodfield, Hitchler et 
al. 2009). 
 
6.3 p16INK4a and p15INK4b   promoter methylation  
 
ESR1 contributes to cell cycle progression by inducing transcription of Cyclin –D1, 
which in association with CDK 4 or CDK 6 effects phosphorylation of Rb (Retino-
blastoma) promoting proliferation (Lamb, Ladha et al. 2000). P16INK4a and p15INK4b are 
members of the INK 4 family, known to be CDK 4 and 6 inhibitors. Even though the 
p15INK4b gene indicates high homology to p16INK4a in the amino acid sequence, they 
seem to show differing patterns of transcriptional activation and epigenetic regulation 
(Ishiguro, Takahata et al. 2006). Generally p15INK4b is not as thoroughly investigated as 
p16INK4a and few data exist concerning the impact of bioactive food compounds on 
p15INK4b promoter methylation. A variety of cancers feature mutations in p16INK4a and 
p15INK4b as well as transcriptional inactivation in association with de novo methylation 
during neoplastic processes. P16INK4a methylation could be a prognostic marker for the 
metastatic potential of a tumor (Ng, Chung et al. 1997; Nakayama, Hibi et al. 2007). In 
untreated Caco-2 cells p16INK4a is prevailingly methylated in contrast to p15INK4b 
promoter region, which seems to be regularily unmethylated. These results agree with 
studies describing different promoter methylation patterns, distinguishing for instance 
leukaemias from colorectal cancer: p15INK4b promoter hypermethylation has been 
found only in leukemias, whereas p16INK4a promoter hypermethylation occured mainly 
in primary colonic tumors (Herman, Jen et al. 1996; Nguyen, Liang et al. 2001). Gene 
expression and promoter DNA methylation of p16INK4a in the colon of mice was shown 
to be dependent on age and folate intake (Fang, Chen et al. 2005). These results 
concur with this studies findings of folic acid treatment to broadly enhance 
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methylation in the p16INK4a- and even more notedly in the p15INK4b - promoter region. 
Downregulation of DNMT3a and upregulation of caspase-3, an important component 
of the apoptotic cascade, was observed in the Caco-2 cell model, after 48h treatment 
with genisteine (data not shown). p16INK4a induction by methylation inhibitors in 
cancer cells was shown to lead to growth inhibition (Auerkari 2006). Our study showed 
genisteine to induce hypomethylation in the p16INK4a promoter region. Similar 
situations were found in benign and cancerogenic breast cells after exposure to 
genisteine: decrease in the expression of DNMTs leading to a hypomethylation of 
several genes associated with telomerase activity and cancer (Li, Liu et al. 2009). Hence 
genisteine seems to be able to induce re-expression of tumor suppressor genes and 
thus to interfere with cell cycle progression of neoplastic cells  .  
For EGCG we observed increased promoter methylation, confirming data suggesting 
that different concentrations of EGCG were able to inhibit the growth of malignant cell 
lines and increase the cell number in G(0)/G(1) phase or rather induce apoptosis in 
many tumors (Butt and Sultan 2009), presumably by impeding DNMT activity and 
reactivating methylation-silenced genes in cancer cells (Fang, Wang et al. 2003). 
Treatment of Caco-2 cells with butyrate clearly decreased p16INK4a promoter 
methylation, possibly leading to its re-expression. Butyrate was reported to lead to cell 
cycle arrest and p16INK4a transcription (Schwartz, Avivi-Green et al. 1998). Upregulation 
of p16INK4a expression was demonstrated to be due to an increase of acetylation and 
degradation of methylation (Shen, Dai et al. 2008). Epigenetic regulation of p16INK4a 
appears to be composed of DNA methylation associated with histone modifications in 
nucleosome-free regions. Thus promoter methylation seems likely to be affected by 
HDAC inhibitors as changes in chromatine configuration can cause altered enzyme 
access to the DNA (Bachman, Park et al. 2003).  
The DNMT inhibitor zebularine almost completely demethylated the p16INK4a promoter 
but had less effect on p15INK4b, propably because p15INK4b already has a low 
methylation status in Caco-2 cells.  
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These results show specified bioactive food compounds to be able to modify CpG 
methylation in the promoter regions of ESR1, p16INK4a and p15INK4b. However the 
degree of change in methylation state of the different genes is variable and often CpG 
methylation might cooperate with additional mechanisms such as histone acetylation 
in the regulation of gene expression. Modulation of the methylation of relevant CpGs 
of ESR1, p16INK4a and p15INK4b by food components might be a way to interfere with 
hormonal signaling in addition to pharmaceutical intervention. Inducing reexpression 
of tumor suppressor genes and impairing ESR1 mediated expression of blood lipid 
regulation might positivley intervene in complex diseases. ESR1 re-expression in ER-
negative breast cancers  could offer the possibility for using hormonal therapy. 
 
 
Ich habe mich bemüht, sämtliche Inhaber der Bildrechte ausfindig zu machen und ihre Zu-
stimmung zur Verwendung der Bilder in dieser Arbeit eingeholt. Sollte dennoch eine Urhe-
berrechtsverletzung bekannt werden, ersuche ich um Meldung bei mir. 
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7 SUMMARY / ZUSAMMENFASSUNG 
 
SUMMARY 
 
Epigenetics generally investigates  heritable changes in gene expression that do not 
involve changes in the underlying DNA sequence. Epigenetic patterns are altered in 
cancer cells and have been studied extensivley, as they influence expression of genes 
regulating cell cycle or encoding hormone receptors, which respond to growth singnals. 
Epigenetic mechanisms are DNA methylation, histone modification and interference of 
small non coding RNAs, whereas especially DNA methylation was assessed accurately, 
detecting global DNA hypomethylation and gene specific hypermethylation as a 
characteristic of senescent and neoplastic cells. Opposed to many genomic alterations 
that emerge during carcinogenesis, DNA methylation is potentially reversible via the 
use of preventive or therapeutic agents, certain bioacitve food components amongst 
them.  
ESR1 (estrogen receptor alpha) appertains to the superfamily of nuclear receptor and 
mediates estrogen effects through its function as ligand-inducible transcription factor. 
ESR1 promoter is known to be hypermethylated in ceveral types of cancer including 
breast and colon cancer. Tumor suppressor genes P16INK4a and p15INK4b are involved in 
the regulation of the mammalian cell cycle. P16INK4a and p15INK4b can undergo genetic 
alterations in neoplastic cells but also methylation dependent inactivation of the 
p16INK4a promoter has been found in various cancer types, such as colorectal, lung and 
breast carcinomas whereas p15INK4b is well documented in haematological 
malignancies. To integrate hormonal and epigenetic activities of selected bioactive 
food components, Caco- 2 cells were treated with folic acid, epigallocatechin-3-gallate 
(EGCG), genistein, butyrate, resveratrol and reference DNA methylation inhibitor 
zebularine and changes in the promoter methylation state of ESR1, p16INK4a and 
p15INK4b  were assessed. Promoter methylation has been measured via bisulfit 
treatment and methylation specific nested PCR and aditionally gene expression of 
ESR1 has been quantified using real time PCR. Treatment with genistein, folate, EGCG, 
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and resveratrol increased and zebularine and butyrate decreased methylation of ESR1. 
Changes in gene expression sparsely responded to treatment, suggesting that CpG 
methylation might cooperate with additional mechanisms such as histone acetylation 
in the regulation of gene expression.  P15INK4b methylation was enhanced by genistein 
and folate and diminished by zebularine, butyrate, EGCG, and resveratrol. Exposure to 
folate entailed p16INK4a hypermethylation whereas all other agents resulted in 
hypomethylation of this gene. These results suggest food ingredients to influence 
epigenetic modification of disease relevant gene expression and might be an effective 
approach to intervene in complex diseases with misregulated ESR1  signaling or cell 
cycle regulation.  
 
 
ZUSAMMENFASSUNG 
 
Epigenetik, die sich mit vererbbaren Zelleingenschaften befasst, welche die 
Genexpression beeinflussen ohne jedoch die DNA-Sequenz zu ändern, scheint auf 
grund ihres Ansprechens auf Umwelteinflüsse der Mittler zwischen Umwelt und 
Genom eines Organismus zu sein. In Krebszellen sind die epigenetischen Muster im 
Vergleich zu gesunden Zellen stark verändert und haben Einfluß haben auf die 
Expression verschiedener Tumorsuppressorgene und Hormonrezeptoren, welche den 
Zellzyklus kontrollieren beziehungsweise auf Wachstumssignale reagieren. Zu den 
epigenetischen Mechanismen zählen die DNA Methylierung, Histon Modifikationen 
und der Einfluß kleiner, nicht kodierender RNAs. Besonders die DNA Methylierung 
wurde bis dato ausführlich erforscht, wobei man feststellte, dass eine umfassende 
DNA Hypomethylierung und genspezifische Hypermethylierung charakteristisch für 
alternde und neoplastische Zellen ist. Im Gegensatz zu den meisten genetischen 
Veränderungen, welche während der Karzinogenese auftreten, kann die DNA 
Methylierung durch den Einfluß präventiver oder therapeutischer Substanzen  
modifiziert werden. Zu diesen Substanzen zählen unter anderem bestimmte bioaktive 
Nahrungsinhaltsstoffe. 
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Östrogenrezeptor alpha (ESR1)  gehört zu der Superfamilie der nuklären Rezeptoren 
und ist durch seine Funktion als Liganden aktivierbarer Transkriptionsfaktor Mediator 
östrogener Einflüße auf die Zellen. In verschiedenen Krebsarten ist die Promoter 
Region von ESR1 hypermethyliert und dessen Expression somit fehlreguliert. Die 
Tumorsuppressorgene p16INK4a und p15INK4b sind Teil der Zellzyklus–Kontrolle. In 
Krebszellen sind diese genetisch verändert aber auch die promoter-
methylierungsabhängige Inaktivierung von p16INK4a  wurde in mehreren Krebsarten 
beobachtet, während selbiger Vorgang im p15INK4b Promoter vornehmlich in diversen 
Blutkrebsarten gefunden wurde. 
Um hormonelle und epigenetische Vorgänge ausgewählter bioaktiver Nahrungs-
bestandteile zu verbinden, wurden Caco-2 Zellen mit mit  Folsäure, Epigallocatechin-3-
gallate (EGCG), Genistein, Butyrat, Resveratrol und Referenz DNA Methylierungs 
Inhibitor Zebularin behandelt und deren Einfluß auf den Promoter Methyleriungsstatus 
des Östrogenrezeptor alpha (ESR1) und der beiden Tumorsuppressorgene p16INK4a und 
p15INK4b bestimmt. 
Die Promotermethylierung wurde durch Bisulfit-Konversion und methylierungs-
spezifischer nested PCR gemessen. Zusätzlich wurde mittels real-time PCR die 
Genexpression von ESR1 quantifiziert. Nach der Zellbehandlung mit Genistein, Folat, 
EGCG und Resveratrol konnte eine verstärkte ESR1 Promotermethylierung festgestellt 
werden, Zebularin und Butyrat verminderten diese. Die Genexpression korrelierte 
jedoch nur teilweise mit den Ergebnissen der Methylierung, was auf einen zuätzlichen 
epigenetischen Mechanismus wie Histonacetylierung in der Expressionsregulation von 
ESR1 schließen lässt.  
P15INK4b Promotermethylierung konnte duch Genistein und Folat verstärkt werden und 
zeigte sich durch Butyrat, EGCG, Resveratrol und Zebularine vermindert. Die stärkste 
Reaktion zeigte die p16INK4a Methylierung nach Behandlung mit Folsäure wobei alle 
anderen Substanzen eine Demethylierung  hervorriefen. Die Ergebnisse dieser Studie 
weisen darauf hin, dass spezifische Nahrungsinhaltsstoffe durchaus einen Einfluss auf 
den epigenetischen Status krankheitsrelevanter Gene haben können. Diese 
Erkenntnisse stellen mögliche Ansatzpunkte  für eine  Prävention und unterstützende 
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Therapie zusätzlich zur pharmakologischen Intervention bei komplexen Krankheiten 
mit fehlreguliertem ESR1-Signalweg oder  fehlerhafter Zellzyklusregulation.   
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8 PROTOCOLS 
8.1 RNeasy® Lipid Tissue Handbook (Qiagen)  
1. If using the TissueLyser, add one stainless steel bead (5 mm mean diameter) per 2   
    ml microcentrifuge tube (not supplied). If working with tissues that are not  
    stabilized in RNAlater RNA Stabilization Reagent, place the tubes on dry ice.  
2.Excise the tissue sample from the animal or remove it from storage. Determine the  
amount of tissue. Do not use more than 100 mg. Proceed immediately to step 3.  
Weighing tissue is the most accurate way to determine the amount. If the tissue 
sample was stored in RNAlater RNA Stabilization Reagent, remove it from the 
reagent using forceps and be sure to remove any crystals that may have formed. RNA 
in harvested tissues is not protected until the tissues are treated with RNAlater RNA 
Stabilization Reagent, flash-frozen, or disrupted and homogenized in step 3. Frozen 
tissues should not be allowed to thaw during handling. The relevant procedures 
should be carried out as quickly as possible. 3. Disrupt the tissue and homogenize the 
lysate using either the TissueRupter (follow step 3a) or TissueLyser (follow step 3b). 
See “Disrupting and homogenizing starting material”, page 12, for more details on 
disruption and homogenization. Note: Incomplete homogenization leads to 
significantly reduced RNA yields and can cause clogging of the RNeasy spin column. 
Homogenization with the TissueRupter or TissueLyser generally results in higher RNA 
yields than with other methods.  
3a. Disruption and homogenization using the TissueRuptor:  
■ Place the tissue in a suitably sized vessel containing 1 ml QIAzol Lysis Reagent. 
Note: Use a suitably sized vessel with sufficient extra headspace to accommodate 
foaming, which may occur during homogenization. Generally, round-bottomed tubes 
allow more efficient disruption and homogenization than conical-bottomed tubes.  
■ Place the tip of the disposable probe into the vessel and operate the TissueRuptor 
at full speed until the lysate is uniformly homogeneous (usually 20–40 s). Proceed to 
step 4. Note: To avoid damage to the TissueRuptor and disposable probe during 
operation, make sure the tip of the probe remains submerged in the buffer. Foaming 
may occur during homogenization, especially of brain tissue. If this occurs, let the 
homogenate stand at room temperature for 2–3 min until the foam subsides before 
continuing with the procedure.  
3b. Disruption and homogenization using the TissueLyser:  
■ Place the tissues in the tubes prepared in step 1.  
■ If the tubes were stored on dry ice, place them at room temperature. Then 
immediately add 1 ml QIAzol Lysis Reagent per tube.  
■ Place the tubes in the TissueLyser Adapter Set 2 x 24.  
■ Operate the TissueLyser for 2 min at 20 Hz. The time depends on the tissue being 
processed and can be extended until the tissue is completely homogenized.  
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■ Rearrange the collection tubes so that the outermost tubes are innermost and the 
innermost tubes are outermost. Operate the TissueLyser for another 2 min at 20 Hz. 
Rearranging he tubes allows even homogenization and carefully pipet the lysates 
into new microcentrifuge tubes (not supplied). Proceed to step 4. Do not reuse the 
stainless steel beads.  
4. Place the tube containing the homogenate on the benchtop at room temperature     
    (15–25°C) for 5 min. This step promotes dissociation of nucleoprotein complexes.  
5. Add 200 μl chloroform. Securely cap the tube containing the homogenate, and     
    shake it vigorously for 15 s. Thorough mixing is important for subsequent phase   
    separation.  
6. Place the tube containing the homogenate on the benchtop at room temperature     
    for 2–3 min.  
7. Centrifuge at 12,000 x g for 15 min at 4°C. After centrifugation, heat the centrifuge   
to room temperature (15–25°C) if the same centrifuge will be used in the later steps 
of this procedure. After centrifugation, the sample separates into 3 phases: an upper, 
colorless, aqueous phase containing RNA; a white interphase; and a lower, red, 
organic phase. For tissues with an especially high fat content, an additional, clear 
phase may be visible below the red, organic phase. The volume of the aqueous phase 
should be approximately 600 μl.  
8. Transfer the upper, aqueous phase to a new tube (not supplied). Add 1 volume  
(usually 600 μl) of 70% ethanol, and mix thoroughly by vortexing. Do not centrifuge. 
Proceed immediately to step 9. Note: The volume of lysate may be less than 600 μl 
due to loss during homogenization and centrifugation. Precipitates may be visible 
after addition of ethanol. Resuspend precipitates completely by vigorous shaking, 
and proceed immediately to step 9.  
9. Transfer up to 700 μl of the sample to an RNeasy Mini spin column placed in a 2 ml  
collection tube (supplied). Close the lid gently, and centrifuge for 15 s at 8000 x g  
(10,000 rpm) at room temperature (15–25°C). Discard the flow-through. Reuse the  
collection tube in step 10.  
10. Repeat step 9 using the remainder of the sample. Discard the flow-through. Reuse  
the collection tube in step 11. Optional: If performing optional on-column DNase 
digestion (see “Important points before starting”), follow steps C1–C4 (page 32) after 
performing this step.  
11. Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and  
centrifuge for 15 s at _8000 x g (_10,000 rpm) to wash the membrane. Discard the 
flow-through. Reuse the collection tube in step 12. After centrifugation, carefully 
remove the RNeasy spin column from the collection tube so that the column does 
not contact the flow-through. Be sure to empty the collection tube completely. Skip 
this step if performing optional on-column DNase digestion (page 32).  
12. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and  
centrifuge for 15 s at 8000 x g (10,000 rpm) to wash the membrane. Discard the flow-
through. Reuse the collection tube in step 13. Note: Buffer RPE is supplied as a 
concentrate. Ensure that ethanol is added to Buffer RPE before use (see “Things to 
do before starting”, page 15).  
13. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and  
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centrifuge for 2 min at 8000 x g (10,000 rpm) to wash the membrane. The long 
centrifugation dries the spin column membrane, ensuring that no ethanol is carried 
over during RNA elution. Residual ethanol may interfere with downstream reactions. 
Note: After centrifugation, carefully remove the RNeasy spin column from the 
collection tube so that the column does not contact the flow-through. Otherwise, 
carryover of ethanol will occur.  
14. Optional: Place the RNeasy spin column in a new 2 ml collection tube (supplied),  
and discard the old collection tube with the flow-through. Close the lid gently, and 
centrifuge at full speed for 1 min. Perform this step to eliminate any possible 
carryover of Buffer RPE, or if residual flow-through remains on the outside of the 
RNeasy spin column after step 13.  
15. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50  
μl RNase-free water directly to the spin column membrane. Close the lid gently. To 
elute the RNA, centrifuge for 1 min at 8000 x g (10,000 rpm).  
16. Repeat step 15 using another volume of RNase-free water, or using the eluate from  
step 15 (if high RNA concentration is required). Reuse the collection tube from step 
15. If using the eluate from step 15, the RNA yield will be 15–30% less than that 
obtained using a second volume of RNase-free water, but the final RNA 
concentration will be higher. 
 
8.2 QIAamp® DNA Mini and Blood Mini Handbook (Qiagen)  
1. Pipet 20 μl QIAGEN Protease (or proteinase K) into the bottom of a 1.5 ml  
microcentrifuge tube.  
2. Add 200 μl sample to the microcentrifuge tube. Use up to 200 μl whole blood, plasma,  
serum, buffy coat, or body fluids, or up to 5 x 106 lymphocytes in 200 μl PBS. If the 
sample volume is less than 200 μl, add the appropriate volume of PBS. QIAamp Mini spin 
columns copurify RNA and DNA when both are present in the sample. RNA may inhibit 
some downstream enzymatic reactions, but not PCR. If RNA-free genomic DNA is 
required, 4 μl of an RNase A stock solution (100 mg/ml) should be added to the sample 
before addition of Buffer AL. Note: It is possible to add QIAGEN Protease (or proteinase K) 
to samples that have already been dispensed into microcentrifuge tubes. In this case, it 
is important to ensure proper mixing after adding the enzyme.  
3. Add 200 μl Buffer AL to the sample. Mix by pulse-vortexing for 15 s. In order to ensure  
efficient lysis, it is essential that the sample and Buffer AL are mixed thoroughly to yield 
a homogeneous solution. If the sample volume is larger than 200 μl, increase the 
amount of QIAGEN Protease (or proteinase K) and Buffer AL proportionally; for example, 
a 400 μl sample will require 40 μl QIAGEN Protease (or proteinase K) and 400 μl Buffer 
AL. If sample volumes larger than 400 μl are required, use of QIAamp DNA Blood Midi or 
Maxi Kits is recommended; these can process up to 2 ml or up to 10 ml of sample, 
respectively. Note: Do not add QIAGEN Protease or proteinase K directly to Buffer AL.  
4. Incubate at 56°C for 10 min. DNA yield reaches a maximum after lysis for 10 min at 56°C.   
     Longer incubation times have no effect on yield or quality of the purified DNA.  
5. Briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops from the inside of  
   the lid.  
6. Add 200 μl ethanol (96–100%) to the sample, and mix again by pulse-vortexing for 15 s.  
 PROTOCOLS 64 
After mixing, briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops from 
the inside of the lid. If the sample volume is greater than 200 μl, increase the amount of 
ethanol proportionally; for example, a 400 μl sample will require 400 μl of ethanol.  
7. Carefully apply the mixture from step 6 to the QIAamp Mini spin column (in a 2 ml  
collection tube) without wetting the rim. Close the cap, and centrifuge at 6000 x g (8000 
rpm) for 1 min. Place the QIAamp Mini spin column in a clean 2 ml collection tube 
(provided), and discard the tube containing the filtrate. Close each spin column in order 
to avoid aerosol formation during centrifugation. Centrifugation is performed at 6000 x g 
(8000 rpm) in order to reduce noise. Centrifugation at full speed will not affect the yield 
or purity of the DNA. If the lysate has not completely passed through the column after 
centrifugation, centrifuge again at higher speed until the QIAamp Mini spin column is 
empty. Note: When preparing DNA from buffy coat or lymphocytes, centrifugation at full 
speed is recommended to avoid clogging.  
8. Carefully open the QIAamp Mini spin column and add 500 μl Buffer AW1 without  
wetting the rim. Close the cap and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the 
QIAamp Mini spin column in a clean 2 ml collection tube (provided), and discard the 
collection. 
tube containing the filtrate. It is not necessary to increase the volume of Buffer AW1 if 
the original sample volume is larger than 200 μl.  
9. Carefully open the QIAamp Mini spin column and add 500 μl Buffer AW2 without  
wetting the rim. Close the cap and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 
min.  
10. Recommended: Place the QIAamp Mini spin column in a new 2 ml collection tube (not  
provided) and discard the old collection tube with the filtrate. Centrifuge at full speed for 
1 min. This step helps to eliminate the chance of possible Buffer AW2 carryover.  
11. Place the QIAamp Mini spin column in a clean 1.5 ml microcentrifuge tube (not  
provided), and discard the collection tube containing the filtrate. Carefully open the 
QIAamp Mini spin column and add 200 μl Buffer AE or distilled water. Incubate at room 
temperature (15–25°C) for 1 min, and then centrifuge at 6000 x g (8000 rpm) for 1 min. 
Incubating the QIAamp Mini spin column loaded with Buffer AE or water for 5 min at 
room temperature before centrifugation generally increases DNA yield. A second elution 
step with a further 200 μl Buffer AE will increase yields by up to 15%. Volumes of more 
than 200 μl should not be eluted into a 1.5 ml microcentrifuge tube because the spin 
column will come into contact with the eluate, leading to possible aerosol formation 
during centrifugation. Elution with volumes of less than 200 μl increases the final DNA 
concentration in the eluate significantly, but slightly reduces the overall DNA yield (see 
Table 5, page 26). For samples containing less than 1 μg of DNA, elution in 50 μl Buffer 
AE or water is recommended. Eluting with 2 x 100 μl instead of 1 x 200 μl does not 
increase elution efficiency. 
 
8.3 EpiTect® Bisulfite Handbook (Quiagen)  
1. Thaw DNA to be used in the bisulfite reaction. Dissolve the required 
number of aliquots of Bisulfite Mix by adding 800 μl RNase-free 
water to each aliquot. Vortex until the Bisulfite Mix is completely 
dissolved. This can take up to 5 min. 
Note: If necessary, heat the Bisulfite Mix–RNase-free water solution to 60°C 
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and vortex again. 
    Note: Do not place dissolved Bisulfite Mix on ice 
2. Prepare bisulfite reactions in 200 μl PCR tubes according to Table 2. 
Add each component in the order listed. 
Note: The combined volume of DNA solution and RNase-free water must 
total 20 μl 
 
    Table 2. Bisulfite Reaction Components 
 
    Component                                                                   Volume per reaction (μl) 
    DNA solution (1 ng – 2 μg)                                           Variable*(maximum 20) 
    RNase-free water                                                                                     Variable* 
    Bisulfite Mix (dissolved), see step 1                                                                 85 
    DNA Protect Buffer                                                                                             35                
    Total volume                                                                                                      140 
 
* The combined volume of DNA solution and RNase-free water must total 20 µl 
 
 
3. Close the PCR tubes and mix the bisulfite reactions thoroughly. Store 
    tubes at room temperature. 
    Note: The DNA Protect Buffer should turn from green to blue after addition 
    to DNA–Bisulfite Mix, indicating sufficient mixing and correct pH for the 
    bisulfite conversion reaction. 
4. Perform the bisulfite DNA conversion using a thermal cycler. 
Program the thermal cycler according to Table 3. 
The complete cycle should take approximately 5 h. 
Note: It is important to choose the largest possible thermal cycler volume 
setting. 
 
Table 3. Bisulfite Conversion Thermal Cycler Conditions 
 
Step                                                Time                                        Temperature ( °C)  
Denaturation                                        5 min                                                          99  
Incubation                                          25 min                                                          60  
Denaturation                                        5 min                                                          99 
Incubation                                          85 min  (1 h 25 min)                                   60 
Denaturation                                        5 min                                                          99  
Incubation                                        175 min  (2 h 55 min)                                   60 
Hold                                                Indefinite                                                     20 
 
 
5. Place the PCR tubes containing the bisulfite reactions into the 
thermal cycler. Start the thermal cycling incubation. 
Important: Since the bisulfite reaction is not overlaid with mineral oil, only 
thermal cyclers with heated lids are suitable for this procedure. It is 
important to use PCR tubes that close tightly. 
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Converted DNA can be left in the thermal cycler overnight without any loss 
of performance. 
 
Cleanup of bisulfite converted DNA 
6. Once the bisulfite conversion is complete, centrifuge the PCR tubes 
containing the bisulfite reactions briefly, then transfer the complete 
bisulfite reactions to clean 1.5 ml microcentrifuge tubes. 
Any precipitants in the solution will not affect the performance or yield of 
the reaction. 
7. Add 560 μl freshly prepared Buffer BL containing 10 μg/ml carrier 
RNA (see “Things to do before starting”, page 15). Mix the solution 
by vortexing and centrifuge briefly. 
Note: Carrier RNA is not necessary when using >100 ng DNA. 
8. Place an EpiTect spin column and collection tube in a suitable rack. 
    Transfer the whole mixture from step 7 into the EpiTect spin column. 
9. Centrifuge the column at maximum speed for 1 min. Discard the 
flow-through, and place the spin column back into the collection 
tube. 
10. Add 500 μl Buffer BW (wash buffer) to the spin column, and 
centrifuge at maximum speed for 1 min. Discard the flow-through, 
and place the spin column back into the collection tube. 
11. Add 500 μl Buffer BD (desulfonation buffer) to the spin column, and 
incubate for 15 min at room temperature. 
If there are precipitates in Buffer BD, avoid transferring them to the spin 
column. 
    Note: It is important to close the lid of the column before incubation. 
12. Centrifuge the column at maximum speed for 1 min. Discard the 
    flow-through, and place the spin column back into the collection 
    tube. 
13. Add 500 μl Buffer BW and centrifuge at maximum speed for 1 min. 
    Discard the flow-through, and place the spin column back into the 
   collection tube 
14. Repeat step 13 once 
15. Place the spin column into a new 2 ml collection tube, and centrifuge 
   the spin column at maximum speed for 1 min to remove any residual 
   liquid. 
   Note: If the purified DNA is intended for use in real-time PCR, extend the 
   centrifugation time to 5 min. 
16. Place the spin column into a clean 1.5 ml microcentrifuge tube (not 
   ovided). Add 20 μl Buffer EB to the center of the membrane. Elute 
  the purified DNA by centrifugation for 1 min at approximately 
  15,000 x g (12,000 rpm). 
  Note: To increase the yield of DNA in the eluate, transfer the spin column 
  to a new 1.5.ml microcentrifuge tube, add an additional 20 μl Buffer EB to 
  the center of the membrane, and centrifuge for 1 min at maximum speed. 
  Combine both eluates. 
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ABSTRACT 
Hormonal regulation and epigenetic control of estrogen receptor alpha (ESR1) is involved in the 
pathogenesis of metabolic disorders and various cancers. To integrate hormonal and epigenetic 
activities of selected bioactive food components, the effect of butyrate, resveratrol, genistein, EGCG, 
folic acid and reference DNMT inhibitor zebularine on the promoter methylation state of ESR1, p16INK4a 
as well as p15INK4b was analyzed in Caco-2 cells. Gene expression of ESR1 was measured by real time PCR 
and methylation of ESR1, p16INK4a and p15INK4b promoter CpG sites were determined by bisulfit 
conversion and methylation-specific PCR. Treatment with genistein, folate and EGCG increased, 
zebularine and butyrate diminished methylation of ESR1. Changes in promoter methylation partly 
corresponded with altered ESR1 gene expression, suggesting implication of additional epigenetic 
pathways such as histone modification, especially for genistein and butyrate. In contrast to p15INK4b, 
p16INK4a promoter region was highly methylated in untreated cells, whereas folic acid increased 
methylation of both tumor suppressor genes. p16INK4a methylation was significantly reduced by butyrate 
and p16INK4a methylation by EGCG and butyrate. 
These results endorse dietary concepts to support therapys, which modulate ESR1 signaling or 
reexpression of silenced ESR1 in hormone mediated complex diseases. 
 
 
INTRODUCTION 
Aberrant methylation of CpG islands located in the promoter region of genes is fairly established as an 
important mechanism leading to abnormal gene activation and has been described in a multitude of 
cancer relevant genes [1]. Cell cycle and cellular growth are under epigenetic control of tumor 
suppressor genes like p16INK4a and p15INK4b, regulating cyclin dependant kinases [2]. Also hormonal 
signals are epigenetically regulated via nuclear receptors such as estrogen receptor alpha (ESR1). ESR1 is 
known to be overexpressed in ER-positive breast cancers and is a target in hormonal therapy [2]. The 
receptor is believed to contribute to tumorigenesis trough stimulatory effects on proliferation of 
mammary cells [3]. Elevated levels of ESR1 in benign breast epithelium appear to indicate an increased 
risk of developing breast cancer [4]. Moreover, ESR1 plays a role in the development of 
arthereosklerosis, as it has been demonstrated to modulate expression of proteins involved in the 
regulation of plasma lipid metabolism, such as apolipoprotein E and LDL receptor. [5]. Variants of the 
ESR1 gene have been associated with components of the metabolic syndrome, including obesity, blood 
levels of HDL-cholesterol, high blood pressure and type 2 diabetes [6]. The nonclassical pathway of 
estrogen action leads to the activation of the MAPK (Mitogen-Activated Protein Kinase) cascade and 
other cell proliferation effects [8]. The classical pathway depends on direct interaction with its receptor, 
mediating gene transcription through binding palindromic ERE (Estrogen Response Elements) or interact 
with transcription factors influencing their activity. ESR1 mediates cell cycle progression through 
transcriptionally regulating estrogen-responsive genes, such as Cyclin D1 [9], a critical mitogenregulated 
cell cycle control element, affecting activation of Rb (Retinoblastoma Protein) [6]. 
Transcriptional regulation of ESR1 involves both, epigenetic mechanisms, including CpG methylation as 
well as histone H3 deacetylation and trans-active factors such as TFAP2 inducing ESR1 transcription. 
Epigenetic chromatin modification might faciliate the access of trans–active factors to enhance or rather 
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decrease transcription [7]. 
Local remodeling of ESR1 promoter chromatin structure by a specific Rb– related protein complex 
strongly correlates with its susceptibility to specific DNA methylation. Methylation associated 
inactivation of the ESR1 gene in ageing -colorectal mucosa could be one of the earliest events in the 
onset of sporadic colorectal tumorgenesis [8]. In comparison, advanced colorectal tumors frequently 
display epigenetical inactivation of p16INK4a [9]. ESR1 transcriptionally regulates cell cycle modulators 
such as Cyclin –D1, which causes the initial inactivation of Rb in association with cyclin dependent kinase 
4, thereby promoting proliferation. Tumor-suppressor -proteins p16INK4a and p15INK4b participate in cell 
growth regulation by inhibiting CDK4 and CDK6. De novo CpG island hypermethylation has also been 
found to be associated with transcriptional silencing of the p16INK4a and p15INK4b genes in a number of 
human neoplasia [10]. 
Diet is known to influence the development of complex diseases such as cancer and the metabolic 
syndrome. Evidence that epigenetic properties of bioacitve food components might contribute to this 
effect becomes more compelling [11]: 
Epigallocatechin-3-gallate (EGCG), the major polyphenol from green tea, is known to inhibit DNMT1 [16] 
and significantly reduce acetylation of histones due to its function as histone- acetyltransferase (HAT) 
inhibitor [17]. Genistein, the most abundant isoflavone found in soybean has been demonstrated to 
restore methylation patterns and gene expression of tumor suppressor genes in neoplastic cultured cells, 
partially through direct inhibition of DNA methyltransferases [18]. These activities were associated with 
inhibited cell growth and induction of apoptosis [19] and might be indirectly due to a modulation of 
NFkB and fork head transkription factors [13]. Resveratrol, described as a possible mimetic of the 
dietary restriction effect, might mediate its effects through maintainance of DNA methylation patterns 
through SIRT-1, a class III histone deacetylase, mediating epigenetic processes [12]. Folic acid regulates 
intracellular levels of SAM (S-adenosyl methionine), the methyl donor for DNA methyltransferases, 
modulating gene stabiltiy and gene expression through altered methylation patterns, both within CpG 
islands and on single CpGs in the genome. Butyrate is a short chain fatty acid produced by the 
gastrointestinal microbiota through the breakdown of non-digestible fibers [13]. Its epigenetic effects 
mainly base on non-competitive inhibition of HDACs, especially class I and II, leading to global histone 
hyperacetylation [14]. An up-regulation of tumor suppressor CDK1A gene after treatment with butyrate 
has been reported with an attendant histone promoter acetylation, potentially explaining its growth 
arrest and apoptotic as well as anti-tumorigenic properties [24]. Zebularine, an orally administerable 
and well established DNA methyltransferase inhibitor, served as a reference in this study. Thaler et al. 
demonstrated a decrease in methylation and a concommittant increase of MnSOD expression in the 
Caco-2 cell line after treatment with zebularine [15]. To find out if and to what extend bioactive 
compounds in diet might affect epigenetic modification of response to estrogenic signals and cancer 
development, we analyzed the influence various bioactive food components have on promoter CpG 
methylation of ESR1, p15INK4b and p16INK4a. 
 
MATERIALS AND METHODS 
 
Cell line and culture conditions 
Human Caco-2 cells (colon carcinoma cell line) were grown at 37°C in a humidified atmosphere (5% CO2), 
in six well tissue culture plates and cultured in RPIM 1640 medium, supplemented with 10% heat 
inactivated fetal bovine serum, 4mM glutamine and 100 units of streptomycin and penicillin respecively. 
48-h treatment was carried out after 14 days of cell gowth. Cell treatments were performed in 
dublicates and pooled for the analysis. 
Agents concentration: butyrat 5 mmol/l, genistein 200 μmol/l, folic acid 200 μmol/l, EGCG 100 μmol/l, 
Resveratrol 10 μmol/ml, Zebularine: 100 μmol/l; 
Cells were washed twice with cooled PBS (4°C) before nucleotide extraction. 
 
Genomic DNA isolation and bisulfite treatment 
DNA was isolated from cells using QIAamp DNA Mini Kit (Qiagen) and bisulfite conversion for detection 
of unmethylated cytosines was performed using the Epitect Bisulfite Kit (Qiagen). Both kits were used 
according to manufacturer's instructions. 
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CpG methylation analysis 
Methylation status of the promoter regions of ESR1 and tumor suppressor genes was determined by 
methylation-specific PCR (MSP), further modified as a nested approach in order to increase sensitivity. 
External primers flanke the CpG- rich promoter regions of the target gene not distinguishing methylated 
from unmethylated nucleotides. PCR products of the external PCR were diluted 1:1000 and used as 
templates in the internal PCR. Two pairs of internal primers are required to recognize bisulfit induced 
alterations in nucleotide sequences of unmethylated cytosines. 
Table I lists the primer sequences and PCR product sizes for each MSP approach. 
External PCR was performed in a 50μl reaction volume, without addition of SybrGreen using the 
Promega PCR Master Mix (Wisconsin, USA). Internal PCR was performed a 10μl reaction volume using 5 
μl Promega PCR Master Mix (Wisconsin, USA) containing 0,5μmol/l MgCl2, 0,2 μl SybrGreen as detection 
dye, 1 μl template and a primer concentration of 5pmol/ l. 
Thermo cycling conditions: 95°C for 5 min, 35 cycles or denaturation - 95°C for 30 sec, annealing 60 sec 
at a specific temperature (ESR1: 58°C external and internal step; p15,p16: 55°C external step, 58°C 
internal step) ,elongation 60 sec at 72°C . Melt curve analysis was performed 50-95°C – 0,5°C each step. 
 
 
EXTERNAL 5´ PRIMER 3` PRIMER 
PRODUCT 
SIZE (bp) 
ESR1 GGYGAGGTGTATTTGGATAGTAGTAAGTT CRAACTCRAAAACACRCTATTAAATAAAA 204 
p15
INK4b
 GAYGTYGGTTTTTTGGTTTAGTTGA AACRCAACCRAACTCAAAACC 139 
p16
INK4a
 AGAAAGAGGAGGGGTTGGTTGG 
ACRCCCRCACCTCCTCTACC 
 
193 
INTERNAL 
UNMETH. 
   
ESR1 TGTTGTTTATGAGTTTAATGTTGTGGTT AAAAAAACCCCCCAAACCATT 124 
p15
INK4b
 GGTTGGTTTTTTATTTTGTTAGAGTGAGGT AACCACTCTAACCACAAAATACAAACACA 80 
p16
INK4a
 TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA 151 
INTERNAL 
METH. 
   
ESR1 ACGAGTTTAACGTCGCGGTC ACCCCCCAAACCGTTAAAAC 
110 
 
p15
INK4b
 GGTTTTTTATTTTGTTAGAGCGAGGC TAACCGCAAAATACGAACGCG 68 
p16
INK4a
 TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 
150 
 
Table I: Primers for ESR1, p15INK4b, p16INK4a CpG methylation analysis [39] 
 
Gene expression analysis 
Total mRNA was extracted from cells using NucleoSpin RNA II (Macherey-Nagel, Germany) according to 
the manufacturer’s instructions and converted into cDNA using Transcriptor First Strand cDNA Synthesis 
Kit (Roche Diagnostics, Germany). Quantification was performed by SybrGreen real-time PCR using the 
Corbett Rotor-Gene 3000. 
The target mRNA expression was normalized to the GAPDH mRNA expression and results compared to 
untreated cells. The primers for gene expression are characterized in table II. Thermo-cycling conditions: 
95°C for 10 minutes followed by cycles at 95°C for 30 sec, further 60 sec 60°C and 30 sec at 72°C. All 
reactions were set-up in a 10 μl final volume using the SensiMix DNA Kit (Quantace, London GB). 
Optimum reaction conditions were obtained with 5 μl 2x PCR master mix, a primer concentration of 
5pmol/ μl and 0,2 μl Sybr-green. 
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 5´ PRIMER 3´ PRIMER 
ESR1 EXPRESSION TGG GCT TAC TGA CCA ACC TG CCT GAT CAT GGA GGG TCA AA 
Table II: Primers for ESR1 gene expression analysis 
 
Data and statistical analyzis  
Real-time PCR runs were analyzed with the Rotor-Gene software Version 6.1 applying comparative 
quantitation. Hypothetical concentrations were calculated and corrected for amplification efficiencies. 
Gene expression results were normalized to GAPDH, which was found to be stably expressed. Gene 
expression and methylation results were calibrated relative to untreated cells and expressed in ratios. 
Mean and standard deviations were calculated using Microsoft Office Excel 2007. Homogeneity of 
variances and signficance of results were tested applying the F-test and a two tails T-test, also in 
Microsoft Office Excel 2007. Results were regarded as significantly different at p<0,05. 
 
 
RESULTS 
ESR1 gene expression and promoter methylation  
Untreated Caco- 2 cells are predominantly methylated at the ESR1 pomoter site in a 56:1 ratio. A 
distinct effect on ESR1´s promoter region methylation has been detected after cell treatment with 
genistein, causing a clear 2,84-fold ± 0,2 (p≤ 0,05) hypermethylation compared to untreated cells, 
whereas nearly no change in mRNA expression could be seen. Treatment with methyl donor folic acid 
results in an almost doubled ESR1´s promoter methylation grade, 1,96-fold ± 0,05 (p≤ 0,01) correlating 
with decreased (0,85 ± 0,57) but no significant decrease in gene expression. A clear 2,03-fold ± 0,07 (p≤ 
0,05) hypermethylation was also observed after cell exposure to EGCG and a slight but not significant 
decrease in gene expression could be seen (0,65 ± 0,02). Treatment with butyrate caused a diminished 
ESR1 expression (0,91 ± 0,15) and a significant decrease in methylation (0,48 ± 0,05; p≤ 0,05). 
Resveratrol marginally impacts any observed gene´s promoter methylation state and only a slight (1,25± 
0,36) but not significant increase in ESR1 mRNA expression could be detected. Methyltransferase 
inhibitor zebularine distinctively diminished methylation in ESR1, p16
INK4a 
and p15
INK4b
. Methylation at 
the ESR1 promoter site decreased significantly, 0,16 ± 0,01 (p≤ 0,01) but no significant change in mRNA 
expression (0,86 ± 0,20) could be observed.  
 
  
p15
INK4b
 and p16
INK4a
 promoter methylation  
In untreated cells p16
INK4a
 CpG rich promoter site is predominantly methylated in contrast to the p15
INK4b
 
promoter region that was found to be regularily unmethylated: the comparison methylated versus 
unmethylated DNA showed a ratio of 5,00E-03
 
for p15
INK4b 
gene and 8,29 E03 for p16
INK4a
. 
Treatment with genistein caused a 1,24- fold ± 0,18 hypermethylation in the p15
INK4b
 promoter site 
compared to untreated cells. In contrast p16
INK4a
 promoter was found to be nearly completely 
demethylated. Exposure to folic acid enhanced p16
INK4a 
methylation 1,66-fold ± 0,40 and also p15
INK4b 
`s 
methylation grade but not as clearly as for p16
INK4a
, 1,21- fold ± 0,27. EGCG treatment caused a 
significant reduction of p15
INK4b 
(0,60 ± 0,01) (p≤ 0,05) and a slight decrease in p16
INK4a
 (0,86 ± 0,41) 
promoter methylation. Exposure to butyrate significantly diminished both, p16
INK4a
  and p15
INK4b 
methylation state 6,92E-02 ± 0,04 (p≤ 0,05) and 0,57 ± 0,01 (p≤ 0,01) compared to untreated cells. 
Resveratrol had almoust no effect on p16
INK4a
 promoter methylation but reduced methylation of 
p15
INK4b 
: 0,62  ± 0,03 (p≤ 0,01). Reference DNMT inhibitor zebularine explicitly diminished methylation 
in the p16
INK4a
 and p15
INK4b 
promoter region: 6,74E-03 ± 0,01 (p≤ 0,05) and 0,64± 0,02 (p≤ 0,01). 
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DISCUSSION 
 
ESR1 Promoter Methylation and Gene expression 
The nuclear receptor ESR1 functions as a transcription factor upon hormonal signals, enhancing the 
transcription of genes involved in the regulation of cell growth. Epigenetic disregulation of ESR1 
expression and concurrent alteration in the integration of hormonal signaling has been associated with 
the development of several diseases, such as the metabolic syndrome and cancer. 
The Caco-2 cell model was chosen as a model for the human gastrointestinal tract, due to its similar 
properties compared to mature enterocytes [18]. 
Our results show untreated cells to be predominantly methylated at the ESR1 promoter site. Caco-2 
cells are derived from human epithelial colorectal carcinoma cells. These results are in agreement with 
studies describing human adenomatous and colon cancer tissue to be hypermethylated at the ESR1 
promoter site [8, 16]. Methylation patterns of free DNA, found in the buffy coat of patients with several 
cancer types, coincide with that of cancer suppressor genes in the tumors [17]. In contrast to Caco-2 
cells, methylation state of ESR1 promoter region in 13 healthy women’s buffy coat DNA turned out to be 
nearly completely unmethylated (data not shown). These differences of the methylation state in 
different tissues need to be considered in the evaluation of effects bioacitve food components have on 
methylation or demethylation, as the original methylation state of the promoter seems to impact the 
degree of treatment induced methylation changes (quod vide results: p15INK4a ). 
An elevated methylation level of the ESR1 promotor region after Caco-2 cells’ exposure to folic acid 
correlated with a reduced gene expression. These findings support preliminary studies suggesting that 
the rate of ESR1 methylation in colonic tissue is modifiable by dietary folate [18]. Zhu and Williams 
hypothesized that development of ER-negative breast cancers, which are unsensitive to hormonal 
therapy, might result from methylation dependant inactivation of ESR1 transcription due to methyl 
deficient diets [19]. Proving that hypothesis an epidemiological study associated higher folate intake 
with reduced risk of developing ER-negative breast cancer, assuming that adequate folate intake is 
particularly important for women with higher risk potential [20]. 
Genistein regulates ESR1 gene expression in a very complex way, amongst others due to its estrogenic, 
epigenetic [21] and tyrosine kinase inhibiting [22] properties. Although promoter methylation increased 
after treatment, we observed an enhanced expression of ESR1. This might be due to a lowered HDAC 
SIRT1 expression, increasing histone acetylation of H3K9 in several gene promoter regions accompanied 
by changes in methylation state [23]. Similar observerations for genistein are being analyzed for IL-8 and 
will be presented elsewhere. 
EGCG treatment caused, in contrast to results for p15INK4a and p16INK4a, a twofold enhanced methylation 
of ESR1 promoter region and a correlating gene expression reduction by half. As EGCG was shown to be 
cancer cell growth inhibiting, these results seem to be conclusive as p15INK4a and p16INK4a are cell cycle 
modulators and ESR1, activated by growth factors, acts as a potent mitogen for epithelial cells [24]. 
Butyrate has been proven to induce histone acetylation by inhibiting histone deacetylases, as well as 
growth arrest or apoptosis [25]. We detected a slight decrease in ESR1 expression after treatment with 
butyrate, as previously shown in breast cancer cells [26], accompanied by clearly diminished 
methylation. CpG islands are significantly more common in deacetylated regions. This finding points 
towards a mechanistic link between DNA methylation and histone acetylation although it is not yet clear 
if histone deacetylation is the reason or the consequence of gene silencing. It might also be possible that 
these epigenetic alterations are responses to stress caused by butyrate treatment [27]. Resveratrol, 
acting as a selective estrogen receptor modulator and modulator of SIRT1 HDAC activity, does seem to 
neither significantly affect methylation nor gene expression of ESR1. Studies working with Caco-2 cells 
investigated global DNA methylation after resveratrol treatment and obtained similar results. In this 
study only one concentration of 10 μmol/l and an incubation time of 48h were used. In contrast, 
investigations on ER-positive breast cancer cells showed resveratrol to induce methylation changes in a 
variety of CpG islands after treatment with 50 μmol/l for 36 hours [28]. 
Although exposure to well established reference DMNT inhibitor zebularine caused a virtually complete 
demethylation of the ESR1 promoter region, almoust no effect on gene expression except for a slight 
decrease could be noted. As gene expression of ESR1 in this study does not always correlate with its 
promoter methylation status after treatment, expression could rather be influenced by CpG islands 
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within exons of the gene or other epigenetic mechanisms, as shown by Zhou et al. They demonstrated 
reactivation of ESR1 gene by HDAC inhibitors to be whithout alteration in promoter DNA 
hypermethylation, suggesting expression of ESR1 to be regulated by histone modification or by a 
combination of DNA methylation and histone modifications [2]. A recent study shows most methylation 
alterations in colon cancer to occur not in promoter regions but 2kb distant, which are termed “CpG 
island shores”. Methylation of these DNA sites was strongly related to gene expression [29]. Moreover 
regulation of ESR1 also comprises trans–active factors such as TFAP2C inducing ESR1 transcription 
through an AP-2 regulatory region in the ESR1 promoter. Epigenetic chromatin modification could 
faciliate admission of trans active factors influencing gene transcription [7]. 
 
p15
INK4b
 and p16
INK4a
 promoter methylation  
ESR1 contributes to cell cycle progression by inducing transcription of Cyclin –D1 [9], cell cycle control 
element, which, in association with CDK 4 or CDK 6 effects phosphorylation of pRb (Retinoblastoma) 
promoting proliferation [6]. P16INK4a and p15INK4b are members of the INK 4 family, known to be CDK 4 
and 6 inhibitors. Even though the p15INK4b gene indicates high homology to p16INK4a in the amino acid 
sequence, they seem to show differing patterns of transcriptional activation and epigenetic regulation 
[30]. Generally p15INK4b is not as thoroughly investigated as p16INK4a and few data exist concerning the 
impact of bioactive food compounds on p15INK4b promoter methylation. A variety of cancers feature 
mutations in p16INK4a and p15INK4b as well as transcriptional inactivation in association with de novo 
methylation during neoplastic processes, leading to uncontrolled cell cycle progression. P16INK4a 
methylation could be a prognostic marker for the metastatic potential of a tumor [10, 31]. In untreated 
Caco-2 cells p16INK4a is prevailingly methylated in contrast to p15INK4b promoter region, which seems to 
be regularily unmethylated. These results agree with studies describing different promoter methylation 
patterns, distinguishing for instance leukaemias from colorectal cancer: p15INK4b promoter 
hypermethylation has been found only in leukemias, whereas p16INK4a promoter hypermethylation 
occured mainly in primary colonic tumors [1, 32]. Gene expression and promoter DNA methylation of 
p16INK4a in the colon of mice was shown to be dependent on age and folate intake [33]. These results 
concur with our findings of folic acid treatment to broadly enhance methylation in the p16INK4a- and 
even more notedly in the p15INK4b - promoter region. In our Caco-2 cell model we observed 
downregulation of DNMT3a and upregulation of caspase-3, an important component of the apoptotic 
cascade after 48h treatment with genisteine (data not shown). p16INK4a induction by methylation 
inhibitors in cancer cells was shown to lead to growth inhibition [34]. Our study showed genisteine to 
induced hypomethylation in the p16INK4a promoter region. Similar situations were found in benign and 
cancerogenic breast cells after exposure to genisteine: decrease in the expression of DNMTs leading to a 
hypomethylation of several genes associated with telomerase activity and cancer [22]. Hence genisteine 
seems to be able to induce reexpression of tumor suppressor genes and thus to interfere with cell cycle 
progression of neoplastic cells [19]. 
For EGCG we observed increased promoter methylation, confirming data suggesting that different 
concentrations of EGCG were able to inhibit the growth of malignant cell lines and increase the cell 
number in G(0)/G(1) phase or rather induce apoptosis in many tumors [35], presumably by impeding 
DNMT activity and reactivating methylation-silenced genes in cancer cells [36] 
Treatment of Caco-2 cells with butyrate clearly decreased p16INK4a promoter methylation, possibly 
leading to its reexpression. Butyrate was reported to lead to cell cycle arrest and p16INK4a transcription 
[37]. Upregulation of p16INK4a expression was demonstrated to be due to an increase of acetylation and 
degradation of methylation [38]. Epigenetic regulation of p16INK4a seems to be composed of DNA 
methylation associated with histone modifications in nucleosome-free regions. Thus promoter 
methylation seems likely to be affected by HDAC inhibitors as changes in chromatine configuration can 
cause altered enzyme access to the DNA. 
The DNMT inhibitor zebularine almost completely demethylated the p16INK4a promoter but had less 
effect on p15INK4b, propably because p15INK4b already has a low methylation status in Caco-2 cells. 
Our results show specified bioactive food compounds to be able to modify CpG methylation in the 
promoter regions of ESR1, p16INK4a and p15INK4b. However the degree of change in methylation state of 
the different genes is variable and often CpG methylation might cooperate with additional mechanisms 
such as histone acetylation in the regulation of gene expression. Modulation of the methylation of 
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relevant CpGs of ESR1, p16INK4a and p15INK4b by food components might be a way to interfere with 
hormonal signaling in addition to pharmaceutical intervention. This could be an effective approach to 
intervene in complex diseases with misregulated ESR1 signaling, for example by improvement of ESR1 
mediated expression of blood lipid regulating proteins in metabolic syndrome. In ER-negative breast 
cancers, induction of ESR1 re-expression could offer the possibility for using hormonal therapy. 
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Abstract Hereditary dispositions and environmental factors such as nutrition, natural and societal 
environment interact on human health. Diet compounds rise increasing interest due to their influence in 
co-regulating epigenetic gene expression. Nutrition and specific food ingredients have been shown to 
alter epigenetic markers such as DNA methylation or histone acetylation involving regulation of genes 
with relevance for fundamental mechanisms such as antioxidative control, cell cycle regulation or 
expression of immune mediators. 
 
Hereditary dispositions 
Interactions between genes and environment are not linear and often include direct and indirect cause 
of events. Many complex diseases are linked to various heritable dispositions like single nucleotide 
polymorphisms (SNP) or allelic translocations. Consequently they have become a main focus in modern 
biomedical research and also started to raise public interest. Single nucleotide polymorphisms are 
common rather than exceptions. SNP´s may determine the efficiency of gene transcription, gene 
translation or protein structure, leading to an altered amount of enzyme and/or –activity, thus 
influencing further metabolic pathways. A SNP can occur within coding sequences of genes, non-coding 
regions of genes or in intergenic regions. SNPs within a coding sequence do not necessarily change the 
functional efficiency of the protein (silent mutations) (Nothnagel, Ellinghaus et al. 2008) (Haiman and 
Stram 2008). 
Upon completion of the human genome project it was confirmed that 99.9 percent of the human 
genome's 3 million base pairs are identical in any person. The remaining 0.1 percent, (mainly SNPs) are 
assumed to play a key role in congenital sensitivity to disease and drug side effects. They also appear to 
influence peoples' variable responses to pharmaceuticals or different penetrance of the same disease. 
The International HapMap (haplotype map) Project aimed to study the scope of these SNP variations in 
different population groups. Clusters of SNPs located on the same chromosome tend to be inherited in 
blocks. It is expected that the outcomes of this project will provide crucial tools that allow researchers to 
detect genetic variations with effects on health and disease. In so called genome-wide association 
studies, researchers compare genomes of individuals with known diseases to a control group of healthy 
ones in order to detect suspicious tag SNPs which might play a role in development/genesis or course of 
disease. ( HapMap project, http://snp.cshl.org/ ) 
A variety of functional SNPs on several genes, covering almost all aspects for cell viability, is well 
described in literature. In superoxide metabolism for example, an increase in superoxide radicals is given 
by the SNP (rs4880) regarding the mitochondrial Superoxide Dismutase (MnSOD) gene (Taufer, Peres et 
al. 2005). Several kinds of cancer (Kang, Lee et al. 2007), Alzheimer disease (Wiener, Perry et al. 2007), 
as well as an accelerated aging process are discussed to be related to this SNP. In opposite, three SNPs 
in the human forkhead box O3A gene (FOXO3A) were statistically significantly associated with longevity. 
Polymorphisms in this gene were indeed associated with the ability to attain exceptional old age, the 
FOXO3A association was considerably stronger in centenarians than in nonagenarians. In nutritional 
sciences, the methylenetetrahydrofolatereductase (MTHFR) gene is well known as it is essential for folic 
acid metabolism (Miyaki, Takahashi et al. 2008). The polymorphism C677T in the MTHFR gene is 
discussed to have an influence in several methylation pathways as for example in the DNA –methylation 
pathway. 
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So far, a multitude of ailments have been correlated with their respective SNPs. Yet, the predictability 
for the development of diseases from the analysis of SNPs still requires larger controlled studies. The 
present difficulty in utilizing SNPs analysis arises from missing the functional relevance of many SNPs. In 
addition, the mostly small and variable penetrance of single SNPs leads to statistical limitations and poor 
reproducibility in many clinical studies associating SNPs and diseases (Janssens, Gwinn et al. 2008). 
The combination of an individual’s relevant SNPs in addition to environmental influences may define his 
risk for developing diseases. Sets of candidate SNPs and experiences from the analysis of the work 
with biobanks need to be evaluated to understand gene – environment interactions (Vineis, Veglia et 
al. 2007). 
 
THE EPIGENOME 
Despite of the genetic code, mammalian cells contain an additional regulatory level which predominates 
over the DNA code: modification of gene expression by altering chromatin. Thus, due to different 
chromatin status, same genetic variants might be for example associated with opposite phenotypes 
depending on different environmental influences. New insights in research clarify the molecular 
pathways by which, amongst others, nutrition and lifestyle factors influence chromatin packaging and 
further health status. Indeed several studies clearly correlate the risk for developing multifactorial 
chronic diseases like cancer, diabetes or obesity with nutritional and lifestyle habits (Mann, Li et al. 1999; 
Johanning, Heimburger et al. 2002; Jirtle and Skinner 2007; Tsugane and Sasazuki 2007). 
Measurable consequences of these influences are alterations in the expression of a growing number of 
genes, caused by remodeling of chromatin and DNA methylation. Methylation of cytosines in DNA, 
histone modifications as well as alterations in the expression level of micro RNA (miRNA) and short 
interference RNA (siRNA) are the mechanisms involved in chromatin remodelling. This topic is being 
studied by the fast evolving research area of epigenetics. The term "epigenome" is used to define a cell's 
overall epigenetic state. Epigenetic modifications can be stably passed over numerous cycles of cell 
division. Some epigenetic alterations can even be inherited from one generation to the next (Anway, 
Memon et al. 2006; Dolinoy, Weidman et al. 2006). Studies conducted by the Department of Community 
Medicine and Rehabilitation of the Umeå University in Sweden showed transgenerational effects due to 
nutritional habits during a child's slow growth period (SGP), the phase of the prepubertal peak in growth 
velocity. Clear correlations with descendants' risk of death from cardiovascular disease and diabetes 
were also seen (Kaati, Bygren et al. 2002). The finding that monozygotic twins are epigenetically 
indistinguishable early in life but, with age exhibit substantial differences in the epigenome, indicates 
that environmentally determined alterations in a cell's epigenetic markers might be responsible (Fraga, 
Ballestar et al. 2005). 
During the development of germ cells and during early embryogenesis DNA is specifically methylated 
and these markers confer genome stability, imprinting of genes, totipotency, correct initiation of 
embryonic gene expression and early lineage development of the embryo (Morgan, Santos et al. 2005). 
According to experiments in the Agouti mouse model, early epigenetic programming is alterable 
through mothers' diet during pregnancy, leading to lifelong modification of selected genes for the 
offspring (Dolinoy, Weidman et al. 2007). Thorough knowledge of both epigenetic and classic genetic 
code is necessary in order to truly understand interactions between the environment and gene 
expression. 
 
EPIGENETIC MECHANISMS 
Epigenetic regulation includes DNA methylation, histone modifications and post-transcriptional 
alteration of gene expression based on microRNA interference. 
 
DNA Methylation 
Basic biological properties of segments such as gene density, replication timing and recombination are 
tightly linked to their guanine –cytosine (CG) content, therefore isochors (DNA fractions > 300 kb on 
average) of the genome can be classified accordingly (Costantini, Clay et al. 2006). CpG islands are 
defined as genomic regions with a GC percentage greater than 50% and with an observed/expected 
CpG(cytosine base followed by a guanine base) ratio greater than 60 %. In mammals, CpG islands 
typically are 200-3.000 base pairs long. CpGs are rare in vertebrate DNA due to the tendency of such 
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arrangements to methylate cytosines to 5-methylcytosines followed by a turn into thymines because of 
spontaneous deamination. The same mechanism seems to be responsible for the inactivation of 
retroviruses by changing the virus sequences [17]. 
The consequences are large DNA -regions low in GC and gene density, clearly visible on isochore maps as 
“genome deserts”. However, some regions escaped large scale methylation and determination during 
evolution and, therefore, show a high amount of GCs, which is generally parallel to a high CpG island 
and gene density (16). CpG islands mostly occur in these isochors, at or near the gene's transcriptional 
start site. Promoters of tissue-specific genes that are situated within CpG islands normally are largely 
unmethylated in expressing and non-expressing tissues (Bestor 2000). There are three known ways by 
which cytosine methylation can regulate gene expression: first 5-methylcytosine can inhibit or hinder 
the association of some transcriptional factors with their cognate DNA recognition sequences, second 
methyl-CpG-binding proteins (MBPs) bind to methylated cytosines mediating a repressive signal and 
third MBPs can interatct with chromatin forming proteins modifying surrounding chromatin, linking DNA 
methylation with chromatin modification (Klose and Bird 2006). Mostly DNA methylation cause a 
repression of mRNA gene expression, however, when CpG methylation blocks a repressor binding site 
within a gene promoter, this may induce a transcriptional activation as shown for Interleukin-8 in breast 
cancer (De Larco, Wuertz et al. 2003) 
DNA -methylation at position five of CpG-cytosines is conducted by DNA methyltransferases (DNMT’s), 
which are expressed in most dividing cells (Schaefer, Ooi et al. 2007). Mammalian DNMT’s can be 
divided in two general classes. DNMT1 enzyme is responsible for the maintenance of global methylation 
patterns on DNA. It preferentially methylates CpGs on hemimethylated DNA (CpG methylation on one 
site of both DNA strands), therefore guaranteeing transfer of methylation marks through the cell cycle in 
eukaryotic cells. The DNMT1 enzyme is directly incorporated in the DNA replication complex. The de 
novo methyltransferases DNMT3a and DNMT3b establish methylation patterns at previously 
unmethylated CpGs. DNMT3L is a DNMT related enzyme which associates with DNMT3a/3b. It 
influences its enzymatic activity while lacking one of its own. Finally, for the DNMT2 enzyme, in 
mammals a biological function remains to be demonstrated (Bestor 2000; Schaefer, Ooi et al. 2007). 
Specific mutations in the DNMT3b gene were found in patients affected by the autosomal recessive 
immune disorder ICF. 
Most DNMT’s contain a sex-specific germline promoter which is activated at specific stages during 
gametogenesis. Genomic methylation patterns are largely erased during proliferation and migration of 
primordial germ cells and reestablished in a sex-specific manner during gametogenesis, resulting in a 
high methylation of the genome. For viability, close regulation of the DNMT genes during these stages 
and during early embryogenesis is needed (Schaefer, Ooi et al. 2007). After fertilization a second phase 
of large epigenetic reprogramming takes place. Upon fertilization, a strong, presumably active DNA 
demethylation can be observed in the male pronucleus while the maternal genome is slowly and 
passively demethylated. Imprinted methylation is maintained for both the paternal and the maternal 
genome. DNA-demethylation occurs until the morula stage, after which de novo methylation is 
observed (Dean, Santos et al. 2003). See figure 1, adapted from Morgan et al 2005 and Dean et al 2003 
(Dean, Santos et al. 2003; Morgan, Santos et al. 2005). 
For targeting DNA de-novo methylation, three mechanisms are described. First, DNMT3 enzymes 
themselves might recognize DNA or chromatin via their conserved PWWP (relatively well-conserved 
Pro-Trp-Trp-Pro residues, present in all eukaryotes) domain. Mouse experiments show that this domain 
is necessary for targeting the enzyme to pericentromeric heterochromatin. In humans, mutations in the 
PWWP domain can cause ICF syndrome Immunodeficiency (Centromere instability and Facial anomalies 
syndrome). Second, by interaction of DNMT’s with site-specific transcriptional repressor proteins 
DNMT’s can be targeted to gene promoter regions. Third, in vitro studies have shown that introduction 
of double stranded RNA corresponding to the promoter region of the target gene leads to its de-novo 
DNA methylation and decreased gene expression, suggesting the existence of an RNAi mediated DNA 
methylation mechanism. However, further efforts are needed to clarify this pathway (Klose and Bird 
2006). 
Their catalytic role aside, DNMTs seem to mediate gene silencing by modifying chromatin via 
proteinprotein interactions. They biochemically interact with histone methyltransferases (HAT) and 
histone deacetylases (HDACs). As mentioned above, binding of MBP’s to methylated CpGs mediates 
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silencing of gene expression by the associaton with chromatin remodeling co-repressor complexes. Thus, 
under certain circumstances, gene silencing by DNA methylation may be attributed directly to chromatin 
modifications. So far, six different methyl-CpG- binding domains (MBD) are known for the MBPs: MBD1 
to 4, MeCP2 and Kaiso. All of them mediate silencing of gene expression by chromatin remodeling 
(Clouaire and Stancheva 2008). For example, the MBD1 and a histone H3 methyltransferase enzyme 
(SetDB1) interact during the cell cycle, linking DNA methylation to rearrangement of chromatin by 
histone methylation (Klose and Bird 2006). Even if no active demethylation for DNA is known, gene 
silencing by DNA methylation is not irreversible. For example, Il-4 expression in undifferentiated T cells 
is silenced via binding of MBD2 on the methylated promoter of the gene (Hutchins, Mullen et al. 2002). 
After differentiation, TH2 cells express the transcription factor GATA-3 which competes with MBD2 for 
binding to the IL-4 promoter. In this case epigenetic factors impose a threshold to be overcome in order 
to achieve efficient gene expression. The binding of MBDs to DNA seems to be for the most domains 
sequence specific. 
In order to achieve DNA methylation, often alterations at the chromatin level must occur before. As 
previously discussed, DNMTs interact with HATs and HDACs. Small modifications of histones by 
acetylation, methylation, phosphorylation and ubiquitation on certain amino acids can alter gene 
expression by chromatin remodeling. The effect of these small modifications on chromatin remodeling 
depends by type, amount and site of modification as well as the interactions as shown in table 1 
(adapted from He and Lehming 2003 (He and Lehming 2003)). 
 
Histone modifications 
Some modifications, including acetylation and phosphorylation, are reversible and dynamic, others, such 
as methylation, are found to be more stable and involved in long term alterations (Cheung and Lau 2005; 
Shahbazian and Grunstein 2007). 
As an attempt to organize the complexity of the different possible modifications, the establishment of a 
“histone code” is a major focus of epigenetic research. Its necessity is demonstrated in the following 
example: We know 24 methylation sites on a histone. The possibility of mono-, di-, or trimethylated 
lysine residues and mono- or dimethylated arginine side chains lead to 3x1011 different histone 
methylation states. The need to distinguish between short-term changes in histone modification 
associated with ongoing processes and changes that have long term effects still pose a problem to be 
solved (Turner 2000; Turner 2002). The significance of some histone modifications has been identified, 
especially regarding acetylation and deacetylation of histones (Shahbazian and Grunstein 2007). Histone 
acetylation is the major factor regulating the degree of chromatin folding, global loss of 
monoacetylation and trimethylation at histone H4, all of which are commonly seen in human tumor cells. 
Histone acetylation also regulates nucleosome assembly. 
Over time, the relationship between DNA-methylation and histone modifications will become clearer 
(Cheung and Lau 2005; Klose and Bird 2006). Several factors are involved in the process of gene silencing 
by DNA-methylation. One prerequisite is attributed to the recruitment of HDACs through the methyl- 
DNA binding motifs, while methylation at Lys9 on H3 is another prerequisite. Methylation of both DNA 
and histones seem to have a reciprocative reinforcing effect in gene silencing. Histone variants like 
macro H2A, accumulated on the inactive X chromosome, have been reported to play a role in gene 
expression regulation. Their presence in the IL-8 promoter-region is connected to tissue related gene 
silencing of the IL-8 gene (30). The comprehension of a histone code will be an important step towards 
in understanding further mechanisms for epigenetic gene expression. 
 
Histone Modification Effect 
 
Histone Modification Effect 
H1 Phosphorylation Chromatin condensation, gene specific 
condensation and repression. 
 Ubiquitination Transcriptional activation 
H2A Acetylation Transcriptional activation 
 Ubiquitination Elusive 
H2B Ubiquitination Prerequisite of H3 methylation 
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 Phosphorylation Chromatin condensation 
 Acetylation Chromatin remodeling 
 Methylation Chromatin stabilization 
H3 Methylation (H3-K4, R17) Transcriptional activation 
 Methylation (H3-K9, K79) Transcriptional repression 
 Acetylation Transcriptional activation 
 Phosphorylation Chromatin condensation; transcriptional 
activation 
 Ubiquitination Nucleosome loosening 
H4 Acetylation Transcriptional activation 
 Methylation (H4-K20) Transcriptional repression 
 Methylation (H4-R3) Transcriptional activation 
Table 1: Consequence of histone modifications on chromatin 
 
Through alteration of gene expression and destabilization of chromatin histone modifications can have 
an impact on the risk of cancer. Modified cancer pathogenesis is linked to varying activities of both HATs 
and HDACs. This mechanism is best described for acute promyelocytic leukemias, where a chromosomal 
translocation leads to inappropriate HDACs activity. A change in HDACs expression was also detected in 
other types of tumors. For example, in gastric cancer, esophageal squamous cell carcinoma, and 
prostate cancer an increased HADC1 expression is related to pathogenesis. In contrast, in colon cancer 
an overexpression of HDAC2 causes a decreased expression of the APC (adenomatous polyposis coli) 
tumor suppressor gene. Another way of influencing the expression of tumor suppressor genes are 
abnormal functions of HDACs, for instance by atypical targeting. These observations lead to the current 
exploration of HDAC inhibitors as anticancer therapeutics. The examined substances aim to shift several 
cell functions which are known to be down regulated in cancer cells. Among other presumed advantages 
of the approach show cancer cells' an increased sensitivity for HDAC inhibitors compared to normal cells, 
thus there may be a possibility to prevent or to decelerate the development of tumours by such 
substances. Overall, the broad range of function promises efficacy at all stages of tumorigenesis. 
Not only HDACs but also HATs influence the risk of developing cancer. Especially in cancer of epithelial 
origin an overexpression or mutation of HAT genes has been detected. Some lines of lung, breast, and 
colorectal cancer have in common a mutation which inactivates a specific HAT. 
Changes of the methylation status of histones have also been observed in some types of cancer. The loss 
of the trimethylated form of the lysine 20 residue of the H4 histone is characteristic for cancer cells. Also, 
the demethylation of lysine 9 on H3 histones increase the formation of B-cell lymphoma in mice 
significantly because of its links to chromatin silencing (Davis and Ross 2007). 
 
Micro RNAs 
In addition to DNA and Histone modifications, micro RNAs are part of the epigenetic gene expression 
regulatory complex. MicroRNAs are small non-coding RNAs that posttranscriptionally regulate the 
expression of complementary messenger RNAs and function as key controllers in a countless number of 
cellular processes, including proliferation, differentiation and apoptosis. Over the last few years, 
increasing evidence has indicated a substantial number of microRNA genes to be subjected to epigenetic 
alterations, resulting in aberrant patterns of expression upon the occurrence of cancer (Guil and Esteller 
2009). 
 
ENVIROMENTAL INFLUENCES 
Early life conditions 
By now, various findings showing the effects of environmental factors on the epigenetic regulation of 
gene expression derive largely from mouse experiments. Environmental factors influencing epigenetic 
gene regulation include more than epigenetically active natural food compounds such as vitamin B12 or 
genistein. Transgenerational effects are for example caused by environmental toxins such as the 
endocrine disruptor vinclozolin, a common fungicide used in vineyards. Vinclozolin were seen to disrupt 
epigenetically the germ line in mice. These effects were transferred through the male germ line for 
several generations. The described mechanism appears to be attributed to a heritable alteration of 
 PUBLICATIONS 87
epigenetic programming of DNA-methylation in the germ line, which alters the transcriptomes of 
developing organs, in this case the testis development (Anway, Memon et al. 2006). 
Early mammalian development is a crucial period for establishing and maintaining epigenetic markers. 
Modifications of the epigenome are not limited to the fetal period but extended to the plastic phase of 
early life. Broad epigenetic reprogramming can be seen after fertilization to achieve totipotency of 
developing embryo cells, while methylation patterns associated with imprinting are sustained. 
Epigenetic modifications settled during fetal development are generally stable passed through cell 
division processes throughout a lifetime. 
Prenatal exposure to famine for instance, as shown in an epidemiological study, is also likely to change 
the epigenetic status. Observed individuals showed less DNA methylation of imprinted IGF-2 gene than 
their unexposed same sexed siblings (Heijmans, Tobi et al. 2008). A further, nutrition-related epigenetic 
alteration have been demonstrated in the viable yellow Agouti (=Avy) mouse model (Dolinoy, Weidman 
et al. 2006). Maternal diet containing bisphenol A (BPA), an estrogenic monomer used in polycarbonate 
plastic production, significantly decreases offsprings methylation of the Avy gene promoter which 
induces reversal to a wild-type phenotype. Maternal nutritional supplementation with methyl-donors 
counteracts the effects from BPA, showing that simple dietary changes may protect against harmful 
epigenetical effects caused by environmental toxins. 
Modified promoter methylation and, accordingly, modified gene expression of the hepatic 
glucocorticoid receptor and the peroxisome proliferator –activated receptor alpha (PPAR alpha), both 
important elements in carbohydrate and lipid metabolism regulation, can be seen in the offspring of rats 
fed a protein restricted diet. The selective methylation of PPAR alpha in the liver without consequences 
for the related transcription factor PPAR gamma demonstrates that maternal nutrition and behavior can 
also influence specific promoter regions rather than being associated with global DNA -methylation 
alteration. Such changes in gene expression and promoter methylation were also seen to be transmitted 
to the next generation without further nutritional challenge for the first generation (Gluckman, Lillycrop 
et al. 2007). 
Finally, the elucidation of the impact of epigenetic modifications on behaviour and psychic health 
presents an intriguing challenge. Rodents experiments show that some epigenetic changes can be 
induced promptly after birth through mother’s physical behaviour toward her newborn (Henry, Kabbaj 
et al. 1994; Darnaudery and Maccari 2008; Zuena, Mairesse et al. 2008) Licked and groomed newborns 
appear to grow up to be relatively brave and calm. In contrast, neglected newborns grow up to be 
nervous and hyperactive. The difference in their behaviour can be explained by analyzing specific 
regions in the brain. The hippocampus of both groups reveal different DNA-methylation patterns for 
specific genes agreeing with the difference in behaviour. This entails a better developing of the 
hippocampus in the licked newborns, possibly by releasing less of the stress hormone cortisol. 
Furthermore, recent research results have demonstrated that complex epigenetic mechanisms have 
long-lasting effects in mature neurons and that they possibly play a vital role in the etiology of major 
psychoses, such as schizophrenia or bipolar disorder. Paternal age at conception is a strong risk factor 
for schizophrenia, explaining about a quarter of all cases. The possible mechanisms for the elevated risk 
may be de novo point mutations or defective epigenetic regulation of paternal genes. The risk might 
also be related to paternal toxic exposures, nutritional deficiencies, suboptimal DNA repair enzymes or 
other factors that influence the reliability of the transfer of genetic information in the constantly 
replicating male germ line. 
 
Pollution and Toxins 
There is now a mounting body of evidence that environmental exposures to toxins, particularly during 
early development, can induce epigenetic changes, which may be transmitted to subsequent 
generations or serve as basis for diseases developed later in life. Either way, epigenetic mechanisms will 
help interpreting toxicogenomic approaches (Reamon-Buettner, Mutschler et al. 2008). 
Air pollution, for instance, particular matters and cigarette smoke, appear to have omnipresent 
toxicological influences on humans. Promotor hypermethylation in early tumorigenesis is likely to have a 
clinical importance, because dissentient promoter methylation in tumor suppressor genes has been 
detected in a large percentage of human lung cancers. Noticeably the p16 gene, which expresses an 
inhibitor of cyclin dependent kinase 4 and 6 consequently, interrupting the cell cycle progression is 
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methylated at its promoter region in 20-65% of the lung tumors. (Hayslip and Montero 2006) Smoking 
habits alter the extent of promoter methylation patterns. Increasing methylation of p16 could be seen 
with increasing smoking duration, packets per years and smoking when a juvenile, whereas methylation 
decreases gradually over time when a person quits smoking. 
Similar effects could be seen in rodents' lung cancer, induced by particulate carcinogens carbon black 
and diesel exhaust, where the tumor cells showed an overmethylation in the p16 promoter region. 
Equal circumstances could be found in murine lung tumors, caused by cigarette smoke. Remarkable 
effects improvements could be achieved by treating rodents with histone deacetylation inhibitors in a 
lung cancer mouse model. A greater than 50 % reduction of tumor growth was seen in treated mice. 
In addition to well-known carcinogens, air pollution components and particulate matter (PM10), nickel 
and beryllium compounds have also been shown to also have an impact on histone acetylation and/or 
altered DNA methylation patterns (Vineis, Hoek et al. 2006). 
 
Diets 
Dietary habits as well as a sedentary lifestyle clearly contribute to today’s increasing number of chronic 
diseases. The influence played by numerous food compounds on the epigenetic machinery is of growing 
interest. The large number of established and probable epigenetic active compounds found in food will 
challenge the understanding of how diet may influence epigenetic gene expression. Studies of dietary 
effects on epigenetic gene regulation are still in their infancy, but first results are shown (Thaler, Karlic 
et al. 2008). Food contains compounds influencing both, DNA methylation and histone modifications. 
However, the consumption of some of these compounds can vary by season, dietary habits, age and 
environment. 
Dietary compounds like vitamin B12 or folic acid are implicated in the regulation of the cytosine 
methylation pathway (Stempak 2002; Choi, Friso et al. 2004; Kim 2004). Vitamin B12 plays a central role 
as it acts as co-factor of the methionine synthetase, remethylating homocysteine to methionine. 
Methionine is further activated to S-adenosylmethionine (SAM), the methyl donor for DNA methylation. 
SAM converts to S-adenosylhomocysteine (Lyko, Ramsahoye et al.) after DNA-methylation. Reversible 
hydrolysis of SAH to homocysteine completes the cycle (figure 2, adapted from Kim 2004 (Kim 2004)). 
Folate, cholin or betaine are potent methyl-donors directly implicated in the DNA-methylation pathway. 
However, under conditions of vitamin B12 depletion, cellular folate accumulates in the methylfolate form 
due to activity of methionine synthetase being blocked, thereby creating a conditional form of folate 
deficiency. Deficiency in vitamin B12 leads also to an accumulation of serum homocysteine. Under 
conditions of elevated homocysteine concentrations, levels of the potent SAM–inhibitor SAH represses 
DNA methylation. The role of folate in DNA-methylation seems to be rather complex. Evidence from 
animal, human, and in vitro studies suggest that folate-dependent DNA methylation is highly complex, 
gene and site specific(Cravo, Fidalgo et al. 1994; Rampersaud, Kauwell et al. 2000; Kim, Baik et al. 2001; 
Kim 2004). These studies have shown that the extent and direction of changes in SAM and SAH in cell 
lines in response to folate deficiency are cell specific and that genomic-site and gene-specific DNA 
demethylation are not affected by the changes in SAM and SAH induced by folate depletion. 
Transgenerational studies on a rat model could furthermore demonstrate that folate deficiency during 
pregnancy impacts on methyl metabolism, but does not effect global DNA methylation in rat foeti 
(Maloney, Hay et al. 2007). A study analyzing the expression of the antioxidative enzyme mitochondrial 
superoxide dismutase (MnSOD) showed that this gene is expressed differently in vegetarians and 
omnivores due to different DNA-methylation patterns in the MnSOD promoter region: vegetarians 
expressed a significant higher amount of MnSOD, showing a low promoter methylation for this gene. 
Inversely, a lower MnSOD expression by a higher MnSOD promoter methylation was seen in omnivores 
(Thaler, Karlic et al. 2008). Several factors which may reduce DNA–methylation machinery in vegetarians 
are discussed. Studies analyzing the B-vitamin status of vegans and vegetarians compared with 
omnivores, showed generally a higher dietary supply of folate and a lower dietary supply of vitamin B12 
(since vitamin B12 intake comes predominantly from animal food products) and methionine for 
vegetarians and vegans (Millet, Guilland et al. 1989; Majchrzak, Singer et al. 2006). Correlations 
between plasma folate and vitamin B12 values were found and study findings showed that vegetarians 
and vegans show higher plasma homocysteine concentrations (Majchrzak, Singer et al. 2006). 
Furthermore, DNA hypomethylation due to high homocysteine levels has been reported in vitro and in 
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vivo (Jamaluddin, Chen et al. 2007; Jiang, Sun et al. 2007). Inhibition of DNA methyltransferase 1 activity 
by 30% and reduced binding of methyl CpG binding protein 2 have also been seen in this context. A 
further study (Geisel, Schorr et al. 2005) comparing vegetarians and omnivores observed a reverse 
correlation between SAH concentrations and DNA global methylation levels in blood. However, this 
study was unable to correlate homocysteine concentrations with the degree of DNA global methylation 
and found no correlation between the degree of CpG methylation of the promoter of the p66Shc gene 
(involved in oxidative stress) and homocysteine, or SAM or SAH levels. 
Other diet derived factors such as diallyl sulfide (Mathers 2006), an organosulfur compound found in 
garlic, genisteine, the main flavanoid in soy (Dolinoy, Weidman et al. 2006), vitamin D3 or all-
transretinoic- 
acids (Krawczyk and Fabianowska-Majewska 2006) have been shown to influence DNA 
methylation by altering histones and chromatin structure. On the histone level, much more food 
compounds show effects on epigenetic gene regulation. Food compounds acting as histone modifiers 
are generally weak enzyme ligands and thus are needed in high concentrations to generate a consistent 
effect and therefore might subtly regulate gene expression (Dashwood, Myzak et al. 2006). A number of 
dietary agents are discussed to have a role in epigenetics as HDAC inhibitors. In the literature well 
described agents in this context are butyrate, diallyl disulfide or sulforaphane. Butyrate is the smallest 
known HDAC inhibitor, and inhibits histone acetylation at high micromolar or low millimolar 
concentrations in vitro, levels nonetheless considered to be achievable in the gastro intestinal tract by 
bacterial metabolism (Dashwood, Myzak et al. 2006). Intriguing examples for a HDAC inhibitor are 
conjugated linoleic acids (Hinshelwood, Melki et al.), which have anticancerogenic and antiatherogenic 
properties. 
Interestingly, CLAs decreases Bcl-2 and induces p21, a known HDAC target. Effects of CLAs on HDACs are 
discussed. Regarding the short chain fatty acids (SCFs) resulting from the microbial fermentation of 
dietary fibers, acetate, propionate and butyrate are taken up by the colonic mucosa. Butyrate is the 
preferred energy source for colonocytes and is transported across the epithelium. Butyrate, and to a 
lesser extent other SCFs, influence gene expression and inflammation primarily through its action as an 
inhibitor of histone deacetylases. Therefore, diet compounds, toxins or medications interfering with the 
colonic fermentation may also modulate potential epigenetic effects generated by the microbial flora. 
By now, there is much work to be done to clarify the influence on histone modifications of a great 
number of dietary factors, alone or in combination and their tissue specific characteristics. A list of 
discussed dietary HDAC activity modulators is shown in table 2. 
Evidences show that a diet rich in vegetables and fruits might prevent some kind of cancers (Research 
2007). In this context, the role of flavonoids is often discussed. Flavonoids can act either in a pro- or 
antioxidative manner depending on their structure and characters. Because of the antioxidative 
properties of some flavonoids, oxidative damage of DNA can be prevented and cancerogenesis altered. 
Guarrera et al postulated recently that flavonoids might influence the gene expression of DNA repair 
genes, which could be a possible explanation for the decrease in tumour development (Guarrera, 
Sacerdote et al. 2007). 
In many animal models caloric restriction has been shown to prevent the development of cancer, 
Thereby the role of sirtuins becomes clearer. In higher eukaryotes, HDACs are grouped in four classes 
(IIV). 
Class I of HDACs are found exclusively in the nucleus, whereas class II of HDACs shuttle between 
nucleus and cytoplasm. Resveratrol activates the HDAC sirtuin 1 (SIRT1) a HDAC belonging to class III 
HDACs. Because of their homology to yeast sir2, class III HDACs belong to the sir2 family (Davis and Ross 
2007). SIRT is an abbreviation for silent mating type information regulation two and there are seven 
groups in humans (Davis and Ross 2007). Sirtuins are nicotineamide adenine dinucleotide (NAD(+)) 
dependent deacetylases which exhibit a well-defined regression during aging that is dramatically 
reverted in transformed cells. . 
Another group of diet related epigenetic active compounds comprise short chain fatty acids (SCFs) 
resulting from the fermentation of dietary fibers. Acetate, propionate and butyrate are taken up by the 
colonic mucosa. Butyrate is the preferred energy source for colonocytes and is transported across the 
epithelium. Butyrate, and to a lesser extent other SCFs, influence gene expression and inflammation 
primarily through its action as an inhibitor of histone deacetylases. Therefore, diets, toxins or 
medications interfering with the colonic fermentation, possibly by an interaction with the composition 
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of the gastro- intestinal microbiota, may modulate SCFs and their epigenetic effects. 
 
 
Nutrition and the immune system 
Expression of Interleukin 8 and the IL23/IL17 pathway is pivotal in the development of chronic 
inflammation such as Crohn's disease (CD) or inflammatory Bowel disease.(Li, Moran et al. 2004; 
McGovern, Rotter et al. 2009) 
IL-8, a member of the CXC chemokine family, is an important activator and chemoattractant for 
neutrophils is primarily regulated at the transcriptional level. IL-8 was shown to be affected by 
methylation of several CpG islands upstream from the promoter region as well as by histone 
modification. Compounds, taking part in DNA methylation pathways and histone acetylation such as 
folic acid, vitamin B12, genistein, zebularine and valproate seem to influence epigenetic modification 
and gene expression of the IL-8 gene in human CACO-2 colon cancer cells. 
By contrast to leukemic blasts, where IL-8 is activated by differentiation(Delaunay, Lecomte et al. 2008), 
immune activated transcription of IL-8 gene may be silenced after differentiation of cells from solid 
tumors such as breast cancer (Chavey, Muhlbauer et al. 2008) through histone deacetylation by 
elements located outside of the immediate 5´flanking region. 
The commensal microflora regulates the local expansion of CD4 T cells producing proinflammatory 
cytokines including IL-17 (Th17 cells) in the colonic lamina propria. (Niess, Leithauser et al. 2008) TH 
cells, which produce IL-17 and IL-17F, two highly homologous cytokines whose genes are located in the 
same chromosomal region have been recently identified to promote tissue inflammation. In these cells 
Histone H3 acetylation and Lysine 4 tri-methylation were specifically associated with IL-17 and IL-17F 
gene promoters. (Akimzhanov, Yang et al. 2007) 
As natural food compounds and diets have been shown to modify the epigenetic regulation of these 
expression of these mediators (Kikuno, Shiina et al. 2008; Romier, Van De Walle et al. 2008) dietary 
strategies might be a possibility in modulating inflammatory diseases. 
 
Nutrition and aging 
Hereditary disposition, environmental elements, individual lifestyle and nutritional factors are known to 
interact with the aging process. These impacts on the aging-process can be divided in intrinsic and 
extrinsic factors. Intrinsic aging (cellular aging) mainly depends on individual hereditary background. 
Extrinsic aging is generated by external factors like smoking, excessive alcohol consumption and poor 
nutrition. During aging, epigenetic changes occur, for instance global DNA demethylation decrease 
contrasting to a CpG island hypermethylation.Progressive loss of global methylation during aging caused 
by passive demethylation is probably due to increasing DNMT1 enzyme inefficiency. Epigenetic changes 
can be seen as important determinants of cellular senescence and organism aging. Sirtuins take part in 
various cellular developments like chromatin remodelling, mitosis, life-span duration and are 
furthermore involved in the regulation of gene expression, insulin secretion and DNA repair. Since NAD 
is one of the critical molecules involved in many metabolic pathways, sirtuins activity is NAD(+) 
dependent and sirtuins control the activity of many other proteins involved in cell growth, it was 
suggested that sirtuins are involved in the elongation of life-span mediated by caloric restriction. Indeed, 
in mammals, caloric restriction decreases the incidence or delays the onset of age-associated diseases 
including cardiovascular diseases, cancer, and osteoporosis as well as neurodegenerative diseases. SIRT1 
is known to be down regulated in senescent cells and during aging. Transcription factors like p53, p73, 
NF-KB, E2F1, p300 and others are also shown to be SIRT1 substrates, suggesting an oncogenetic 
potential for SIRT 1. In an ongoing process more and more sirtuin inhibitors are being discovered. 
Recent detections are sirtinol, cambinol, dihydrocoumarin and indole, coumarin and indoles being 
natural food compounds. Coumarin can be found in dates, dihydrocoumarin naturally in sweet clover 
and synthetically manufactured in foods and cosmetics. Indole is produced by intestinal bacteria as 
product of tryptophan degradation. Early findings about this novel class of HDACs are encouraging. Even 
more intensive research will be necessary to clarify connections between sirtuins, nutrition, aging and 
cancer genesis. 
It has been suggested that sirtuins may be involved in the elongation of life-span mediated by caloric 
restriction transcription factors, such as p53, p73, NF-KB, E2F1, p300 and others are shown to be SIRT1 
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substrates. Currently sirtuin inhibitors from natural compounds are being discovered (Kwon, Owa et al. 
1998; Akkermans, Kleerebezem et al. 2007). Intensive research will be necessary to clarify any 
connections between sirtuins, nutrition, aging and cancer genesis. 
 
CONCLUSION 
Epigenetic mechanisms contribute to the control of gene expression as a result of environmental signals 
due to their inherent malleability. Considerable evidence suggests that nutritional imbalance and 
metabolic disturbances during critical time windows of development, may have a persistent effect on 
the health of the concerned individulas and may even be transmitted to the next generation. For 
example, in addition to a "thrifty genotype" inheritance, individuals with obesity, type 2 diabetes, and 
metabolic syndrome with an increased risk of cardiovascular diseases may have suffered 
improper ”epigenetic programming" during their fetal/postnatal development due to maternal 
inadequate nutrition and metabolic disturbances and also during their lifetime, that could even be 
transmitted to the next generation(s), (Asim K Duttaroy, Evolution, Epigenetics, and Maternal Nutrition, 
Darwins Day Celebration, 2006). 
The balance between genetic and epigenetic impacts in development of malignancy is therefore 
changing from childhood to later age. Whereas e.g. the majority of childhood tumors are associated 
with an inherited genetic or epigenetic (e.g., imprinted) burden, this balance shifts in favor of acquired 
epigenetic and genetic hits in tumors of adults and elderly (Haslberger, Varga et al. 2006) ( Fig .3). 
As predicted by Rupert Riedl working with the so-called “General Systems Theory” the evolution of 
complex adaptation requires a match between the functional relationships of the phenotypic characters 
and their genetic representation [60]. Regarding to Riedl “evolvability” results from such a match. If the 
epigenetic regulation of gene expression "imitates" the functional organization of the traits then the 
improvement by mutation and selection is facilitated. Riedl predicts that the evolution of the genetic 
representation of phenotypic characters tends to favor those representations which imitate the 
functional organization of the characters. Imitation means that complexes of functionally related 
characters shall be "coded" as developmentally integrated characters but coded independently of 
functionally distinct character complexes (Wagner and Laubichler 2004). 
Epigenetic mechanisms thus appear as a machinery of recursive feedback which determines the average 
rate of change of characters at all levels from molecules to cells, organisms and their 
environment(Haslberger, Varga et al. 2006). A better description of role of the epigenetic machinery in 
the interaction between hereditary and environmental interactions will also add to our understanding of 
evolution and an improved, individual and preventive health care system. 
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10.3 Abstracts for poster presentations 
 
19th International Congress of Nutrition, Bangkok, Oct. 4-9 2009 
 
REGULATION OF IL-8 AND IL-17 EXPRESSION BY BUTYRATE, FOLIC ACID, AND GENISTEIN 
INCLUDES DNA METHYLATIONAND HISTONE ACETYLATION 
 
E. Aumueller, C. Berner, A. Gauck, P. Klein, A. G. Haslberger 
Department of Nutrition, University of Vienna 
 
IL-8 and IL-17 regulate interactions between immune cells and epithelia in the GI-tract, involving 
epigenetic mechanisms. Because of the epigenetic activities of the SCF (short chain fatty acid) 
butyrate, produced by intestinal microbiota, genistein and folic acid we analyzed effects on histone 
acetylation and DNA-methylation on interleukin-8 and -17 genes. 
 
We analyzed gene expression by real time PCR, DNA-methylation by bisulfite sequencing PCR, and 
histone acetylation by Chromatin immunoprecipitation in the CACO-2 cell line model. 
 
IL-8 and IL-17 expression was increased by genistein, butyrate, and folic acid. Folic acid stimulated 
the IL-8-DNA-methylation on the sites -1342 and -1412. Butyrate stimulated the histone acetylation 
on H3 lysine 9 at IL-8. Genistein and butyrate also stimulated apoptosis relevant caspase-3. 
Changes in butyrate producing GI-microbiota (Clostridium cluster IX and XIVa) were found due to 
nutrition. 
 
As the levels of genistein, folic acid, and butyrate in the GI-tract can be influenced by nutrition, 
nutritional concepts may be feasible to interfere with IL-8 and IL-17 expression in inflammatory GI 
diseases. 
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19th International Congress of Nutrition, Bangkok, Oct. 4-9 2009 
 
COMBINED HEDERITARY/GENETIC AND EPIGENETIC ASPECTS IN GENETIC TESTING OF 
COMPLEX DISEASES AND NUTRIGENETICS 
 
S.Englert, C.Berner, A.G.Haslberger* 
alexander.haslberger@univie.ac.at 
Department for Nutritional Sciences, University of Vienna 
 
Genetic testing and preventive health care based on the use of Single Nucleotide Polymorphisms 
(SNPs) was criticized because of methodological errors and low penetrance. The potential need 
considering epigenetic aspects in the genetic analysis of complex diseases and nutritional disorders 
is being discussed. To evaluate epigenetic influences in genetic and nutrigenetic testing, 
interactions of SNPs and epigenetic DNA-methylation are analyzed. 
Penetrance of selected SNPs with relevance to selected cancers are evaluated calculating odds 
ratios (OR) and p-values (p) in meta-analysis. In comparison, relevance of DNA-methylation is 
assessed. 
Whereas penetrance of analyzed SNPs was usually found to be low, strong correlations of 
epigenetic DNA-methylation were found. For example, ORs of 1,5 (p≈0.55, after Bonferroni-
correction) were found for the common A148T variant of the tumor-suppressor-gen p16 in 
colorectal cancer. In contrast, hypermethylation was found in about 30 % of sporadic colorectal 
cancer. Hypermethylation of tumor-suppressor-genes such as p16 is reversible by nutritional 
components such as Genistein in vitro. 
These findings underline the importance of integrating hereditary genetic aspects in concepts for 
genetic and nutrigenetic analysis in public health care.  
 
 
 
 
NuGOweek 2009, Montecatini Terme, Aug. 31-Sep. 3 2009 
 
EPIGENETIC REGULATION OF IL-8 AND E-CADHERIN GENE EXPRESSION BY BUTYRATE, FOLIC 
ACID, AND GENISTEIN INCLUDES DNA-METHYLATION AND HISTONE ACETYLATION  
 
E. Aumueller, A. Gnauck, C. Berner, P. Klein, A. G. Haslberger 
Department of Nutrition, University of Vienna 
Alexander.haslberger@univie.ac.at 
 
The expression of IL-8 and E-Cadherin regulates the interactions between immune cells and 
epithelia in the GI-tract involving epigenetic mechanisms. Because of the epigenetic activities of the 
SCF butyrate, produced by intestinal microbiota, as well as genistein and folic acid we analyzed 
effects on histone acetylation and DNA-methylation on the expression of IL-8 and E-Cadh. 
 
Gene expression was analyzed by real time PCR, DNA-methylation by Methylation Specific PCR 
(MSP), bisulfite sequencing PCR (BSP) and histone acetylation by Chromatin immunoprecipitation 
in the CACO-2 cell line model. 
 
IL-8 and E-Cadh expression was increased by genistein, butyrate, folic acid and the DNA 
methyltransferase inhibitor zebularine.  Whereas zebularine decreased DNA methylation of E-Cadh 
and IL-8 (on the sites -1342 and -1412), butyrate enhanced the histone acetylation on H3 lysine 9 at 
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IL-8. Genistein and butyrate also stimulated the apoptose relevant caspase3. Changes in butyrate 
producing GI-microbiota (Clostridium cluster IX and XIVa) were found due to nutrition. 
 
          As the levels of genistein, folic acid, and butyrate in the GI-tract can be modulated by nutrition, 
nutritional concepts may be feasible to interfere with epigenetic mechanisms in inflammatory GI 
diseases. 
 
 
 
 LEBENSLAUF 98 
11 LEBENSLAUF 
Persönliche Daten: 
Carolin Berner                                                                                                       
geb. 17.06.1984, Stuttgart                                                               
E-Mail: carolin.berner@gmx.net  
 
Ausbildung: 
Grundschule: Schachen, Lindau (D) 1990-1994 
Gymnasium: Valentin Heider Gymnasium, Lindau (D)  1994-2003 
Abitur  06/2003 
Studium: 
Ernährungswissenschaften, Universität Wien seit 03/2004 
1. Studienabschnitt abgeschlossen  05/2008 
Wahlschwerpunkt im 2. Abschnitt: 
Lebensmitteltechnologie  
 
Humanmedizin, Medizinische Universität Wien seit 10/2006 
 
 
Praktika 
Kraft Foods Bludenz - Qualitätsmanagement  07-09/2007 
Famulaturen   
Innere Medizin, LKH Bregenz  07/2008 
Primärversorgung, LKH Bregenz 08/2008 
Pathologie, Klinikum Friedrichshafen  09/2008 
 
 
Publikationen 
Thaler R., Aumueller E., Berner C., Schuster J., Haslberger A.G.: Interaction of hereditary and 
epigenetic mechanisms in the regulation of immune and ageing relevant gene 
expression. In: Epigenetics and Human Health – linking hereditary, environmental and 
nutritional aspects. (Haslberger A.G., editor), in preparation 
Poster 
S. Englert, C. Berner, A.G. Haslberger : Combined hederitary/genetic and epigenetic aspects 
in genetic testing of compley diseases and nutrigenetics. International Congress of 
Nutrtion, Oct. 4-9 2009, Bangkok 
 LEBENSLAUF 99
Aumueller E., Berner C., Gnauck A., Klein P., Haslberger A.G.: Regulation of Il-8 and Il-17 
expression by butyrate, folic acid, and genistein includes DNA methylation and histone 
acetylation. International Congress of Nutrtion, Oct. 4-9 2009, Bangkok 
Aumueller E., Gnauck A., Berner C., Klein P., Haslberger A. G.: Epigenetic regulation of IL-8 
and E-Cadherin gene expression by butyrate, folic acid, and genistein includes DNA 
methylation and histone acetylation. NuGOweek 2009, Aug. 31-Sep. 3, 2009, 
Montecatini Terme 
 
 
